WHO Drug Information, Vol. 30, No. 3, 2016                            Recommended INN: List 76




International Nonproprietary Names
for Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names: List 76
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of
Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health
Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4
(EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary
Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does
not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in
Cumulative List No. 16, 2015 (available in CD-ROM only).



Dénominations communes internationales des Substances
pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES: Liste 76
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du
choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques
[Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9);
résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation
mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de
l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–113) et
recommandées (1–74) dans la Liste récapitulative No. 16, 2015 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales para las Sustancias
Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS: Lista 76
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones
Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud,
1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4
(EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las
denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones
Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las
Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se
encuentran reunidas en Cumulative List No. 16, 2015 (disponible sólo en CD-ROM).




                                                                                                477
Recommended INN: List 76                       WHO Drug Information, Vol. 30, No. 3, 2016




 Latin, English, French, Spanish:   Chemical name or description; Molecular formula; Graphic
 Recommended INN                    formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule
                                    développée
 DCI Recomendada
                                    Nombre químico o descripción; Fórmula molecular; Fórmula
                                    desarrollada



 acebilustatum
 acebilustat                          4-{[(1S,4S)-5-({4-[4-(1,3-oxazol-
                                      2-yl)phenoxy]phenyl}methyl)-
                                      2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl}benzoic acid

 acébilustat                          acide 4-{[(1S,4S)-5-({4-[4-(1,3-oxazol-
                                      2-yl)phénoxy]phényl}méthyl)-
                                      2,5-diazabicyclo[2.2.1]heptan-2-yl]méthyl}benzoïque

 acebilustat                          ácido 4-{[(1S,4S)-5-({4-[4-(1,3-oxazol-
                                      2-il)fenoxi]fenil}metil)-2,5-diazabiciclo[2.2.1]heptan-
                                      2-il]metil}benzoico

                                       C29H27N3O4




 alalevonadifloxacinum
 alalevonadifloxacin                  (5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-
                                      5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-
                                      2-carboxylic acid

 alalévonadifloxacine                 acide (5S)-8-[4-(L-alanyloxy)pipéridin-1-yl]-9-fluoro-
                                      5-méthyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-
                                      2-carboxylique

 alalevonadifloxacino                 ácido (5S)-8-[4-(L-alaniloxi)piperidin-1-il]-9-fluoro-
                                      5-metil-1-oxo-6,7-dihidro-1H,5H-pirido[3,2,1-ij]quinolina-
                                      2-carboxílico

                                       C22H26FN3O5




478
WHO Drug Information, Vol. 30, No. 3, 2016                                         Recommended INN: List 76


 albusomatropinum #
 albusomatropin                        human serum albumin (residues 1-585) fusion protein with
                                       human somatotropin (growth hormone) (residues 586-
                                       776), produced in yeast cells (Saccharomyces cerevisiae)

 albusomatropine                       albumine sérique humaine (résidus 1-585) protéine de
                                       fusion avec la somatotropine humaine (hormone de
                                       croissance) (résidus 586-776), produit par culture de
                                       levure (Saccharomyces cerevisiae)

 albusomatropina                       albúmina sérica humana (restos 1-585) proteína de fusión
                                       con la somatotropina humana (hormona de crecimiento)
                                       (restos 586-776), producida mediante cultivo de levadura
                                       (Saccharomyces cerevisiae)


                                        Sequence/ Séquence / Secuencia
                                        DAHKSEVAHR FKDLGEENFK ALVLIAFAQY                  LQQCPFEDHV       KLVNEVTEFA       50
                                        KTCVADESAE NCDKSLHTLF GDKLCTVATL                  RETYGEMADC       CAKQEPERNE       100
                                        CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN                  EETFLKKYLY       EIARRHPYFY       150
                                        APELLFFAKR YKAAFTECCQ AADKAACLLP                  KLDELRDEGK       ASSAKQRLKC       200
                                        ASLQKFGERA FKAWAVARLS QRFPKAEFAE                  VSKLVTDLTK       VHTECCHGDL       250
                                        LECADDRADL AKYICENQDS ISSKLKECCE                  KPLLEKSHCI       AEVENDEMPA       300
                                        DLPSLAADFV ESKDVCKNYA EAKDVFLGMF                  LYEYARRHPD       YSVVLLLRLA       350
                                        KTYETTLEKC CAAADPHECY AKVFDEFKPL                  VEEPQNLIKQ       NCELFEQLGE       400
                                        YKFQNALLVR YTKKVPQVST PTLVEVSRNL                  GKVGSKCCKH       PEAKRMPCAE       450
                                        DYLSVVLNQL CVLHEKTPVS DRVTKCCTES                  LVNRRPCFSA       LEVDETYVPK       500
                                        EFNAETFTFH ADICTLSEKE RQIKKQTALV                  ELVKHKPKAT       KEQLKAVMDD       550
                                        FAAFVEKCCK ADDKETCFAE EGKKLVAASQ                  AALGLFPTIP       LSRLFDNAML       600
                                        RAHRLHQLAF DTYQEFEEAY IPKEQKYSFL                  QNPQTSLCFS       ESIPTPSNRE       650
                                        ETQQKSNLEL LRISLLLIQS WLEPVQFLRS                  VFANSLVYGA       SDSNVYDLLK       700
                                        DLEEGIQTLM GRLEDGSPRT GQIFKQTYSK                  FDTNSHNDDA       LLKNYGLLYC       750
                                        FRKDMDKVET FLRIVQCRSV EGSCGF                                                        776

                                        Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                        53-62     75-91      90-101 124-169 168-177 200-246 245-253
                                        265-279 278-289 316-361 360-369 392-438 437-448 461-477
                                        476-487 514-559 558-567 638-750 767-774


 asunerceptum #
 asunercept                            fusion protein for immune applications (FPIA) comprising
                                       the Homo sapiens FAS (Fas cell surface death receptor,
                                       TNFRSF6, tumor necrosis factor receptor (TNFR)
                                       superfamily member 6, FAS1, APO-1, CD95) extracellular
                                       domain, fused with Homo sapiens immunoglobulin G1 Fc
                                       fragment;
                                       Homo sapiens FAS precursor fragment 26-172 (1-147) -
                                       gamma1 chain H-CH2-CH3 fragment [Homo sapiens
                                       IGHG1*03 (hinge 5-15 (148-158), CH2 (159-268), CH3
                                       (269-373), CHS (374-375))] (148-375); dimer (148-
                                       148':154-154':157-157')-trisdisulfide

 asunercept                            protéine de fusion pour applications immunitaires (FPIA)
                                       comprenant le domaine extracellulaire d’Homo sapiens
                                       FAS (récepteur de mort membranaire Fas, TNFRSF6,
                                       membre 6 de la superfamille des récepteurs du facteur de
                                       nécrose tumorale (TNFR), FAS1, APO-1, CD95), fusionné
                                       au fragment Fc de l’immunoglobuline G1 d’Homo sapiens;
                                       Homo sapiens FAS fragment 26-172 du précurseur (1-
                                       147)-fragment H-CH2-CH3 de la chaîne gamma1 [Homo
                                       sapiens IGHG1*03 (charnière 5-15 (148-158), CH2 (159-
                                       268), CH3 (269-373), CHS (374-375))] (148-375); dimère
                                       (148-148':154-154':157-157')-trisdisulfure




                                                                                                                                 479
Recommended INN: List 76                  WHO Drug Information, Vol. 30, No. 3, 2016




 asunercept                proteína de fusión para aplicaciones inmunitarias (FPIA)
                           que comprende el dominio extracelular de Homo sapiens
                           FAS (receptor de muerte Fas de membrana, TNFRSF6,
                           miembro 6 de la superfamilia de receptores del factor de
                           necrosis tumoral (TNFR), FAS1, APO-1, CD95), fusionado
                           con el fragmento Fc de la inmunoglobulina G1 de Homo
                           sapiens;
                           FAS de Homo sapiens fragmento 26-172 del precursor (1-
                           147) -fragmento H-CH2-CH3 de la cadena gamma1 [Homo
                           sapiens IGHG1*03 (bisagra 5-15 (148-158), CH2 (159-
                           268), CH3 (269-373), CHS (374-375))] (148-375); dímero
                           (148-148':154-154':157-157')-trisdisulfuro
                           Fused chain / chaine fusionnée / cadena fusionada
                           QVTDINSKGL ELRKTVTTVE TQNLEGLHHD GQFCHKPCPP                                 GERKARDCTV             50
                           NGDEPDCVPC QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV                                 EINCTRTQNT            100
                           KCRCKPNFFC NSTVCEHCDP CTKCEHGIIK ECTLTSNTKC                                 KEEGSRSCDK            150
                           THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV                                 VVDVSHEDPE            200
                           VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD                                 WLNGKEYKCK            250
                           VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ                                 VSLTCLVKGF            300
                           YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV                                 DKSRWQQGNV            350
                           FSCSVMHEAL HNHYTQKSLS LSPGK                                                                       375

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intrachain FAS                      34-48 38-57         60-76      79-94
                                                                82-102 104-118 121-132 124-140
                                                                34'-48' 38'-57'     60'-76' 79'-94'
                                                                82'-102' 104'-118' 121'-132' 124'-140'
                                        IGHG1 (C23-C104) 189-249 295-353
                                                               189'-249' 295'-353'
                           Interchain IGHG1 (h5, h 11, h 14) 148-148' 154-154' 157-157'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           FAS:
                           93, 111, 93', 111': complex mono-, bi-, tri- and tetra-antennary oligosaccharides, partially
                           sialylated, oligosaccharides complexes de structure ramifiée (de 1 à 4 branches), partiellement
                           sialylés, oligosacáridos complejos mono-bi, tri y tetra-antenado, parcialmente sialilados
                           IGHG1 CH2 N84.4:
                           225, 225': complex mono- and biantennary non-sialylated oligosaccharides, oligosaccharides
                           complexes de structure ramifiée (de 1 à 2 branches) non-sialylés, oligosacáridos complejo
                           mono- and biantenado non-sialilado

                           Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                           modificaciones post-traduccionales:
                           H CHS K2 C-terminal lysine clipping, coupure de la lysine C-terminale, supresión de lisina C-terminal:
                           375, 375'




 avacopanum
 avacopan                  (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-
                           6-methylbenzoyl)-N-[4-methyl-
                           3-(trifluoromethyl)phenyl]piperidine-3-carboxamide

 avacopan                  (2R,3S)-2-[4-(cyclopentylamino)phényl]-1-(2-fluoro-
                           6-méthylbenzoyl)-N-[4-méthyl-
                           3-(trifluorométhyl)phényl]pipéridine-3-carboxamide

 avacopán                  (2R,3S)-2-[4-(ciclopentilamino)fenil]-1-(2-fluoro-
                           6-metilbenzoil)-N-[4-metil-
                           3-(trifluorometil)fenil]piperidina-3-carboxamida

                           C33H35F4N3O2




480
WHO Drug Information, Vol. 30, No. 3, 2016                             Recommended INN: List 76




 bazlitoranum
 bazlitoran                            all-P-ambo-2'-deoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-
                                       (3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-deoxy-
                                       5-methyl-P-thiocytidylyl-(3'→5')-7-carba-2'-deoxy-
                                       P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-
                                       (3'→5')-2'-O-methyluridine

 bazlitoran                            tout-P-ambo-2'-déoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-
                                       (3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-déoxy-
                                       5-méthyl-P-thiocytidylyl-(3'→5')-7-carba-2'-déoxy-
                                       P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-
                                       P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-
                                       (3'→5')-2'-O-méthyluridine

 bazlitorán                            todo-P-ambo-2'-desoxi-P-tiocitidilil-(3'→5')-
                                       P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-
                                       P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-
                                       P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-
                                       metil-P-tiouridilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-
                                       (3'→5')-7-carba-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-
                                       (3'→5')-P-tiotimidilil-(3'→5')-
                                       2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-
                                       2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-
                                       2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metiluridina
                                       C179H233N52O101P17S17
                                       (3'-5')d(P-thio)(C-T-A-T-C-T-rGm-rUm-m5C-c7G-
                                                        T-T-C-T-C-T-rGm-rUm)
                                        Legend:
                                        rGm = 2'-O-méthylguanosine
                                        rUm = 2'-O-méthyluridine
                                        m5C = 2'-deoxy-5-methylcytidine
                                        c7G = 2'-deoxy-7-carbaguanosine (C replaces N)

 bevacizumabum beta #
 bevacizumab beta                      immunoglobulin G1-kappa, anti-[Homo sapiens VEGFA
                                       (vascular endothelial growth factor A, VEGF-A, VEGF)],
                                       humanized monoclonal antibody;




                                                                                                  481
Recommended INN: List 76           WHO Drug Information, Vol. 30, No. 3, 2016


                           gamma1 heavy chain (1-453) [humanized VH (Homo
                           sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01)
                           [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K
                           (220) (124-221), hinge (222-236), CH2 (237-346), CH3
                           (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide
                           with kappa light chain (1’-214’) [humanized V-KAPPA
                           (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                           (232-232":235-235")-bisdisulfide

 bévacizumab bêta          immunoglobuline G1-kappa, anti-[Homo sapiens VEGFA
                           (facteur de croissance A de l’endothélium vasculaire,
                           VEGF-A, VEGF)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-453) [VH humanisé (Homo
                           sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01)
                           [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K
                           (220) (124-221), charnière (222-236), CH2 (237-346), CH3
                           (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure
                           avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                           (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           dimère (232-232":235-235")-bisdisulfure

 bevacizumab beta          inmunoglobulina G1-kappa, anti-[Homo sapiens VEGFA
                           (factor de crecimiento A endotelial vascular, VEGF-A,
                           VEGF)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-453) [VH humanizado (Homo
                           sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01)
                           [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K
                           (220) (124-221), bisagra (222-236), CH2 (237-346), CH3
                           (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro
                           con la cadena ligera kappa (1’-214’) [V-KAPPA
                           humanizado (Homo sapiens IGKV1-16*01 (88.40%) -
                           IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                           (108'-214')]; dímero (232-232":235-235")-bisdisulfuro




482
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76




 blontuvetmabum #
 blontuvetmab                          immunoglobulin G2_V-kappa-C-lambda, anti-[Homo
                                       sapiens MS4A1 (membrane-spanning 4-domains
                                       subfamily A member 1, CD20)], caninized monoclonal
                                       antibody;
                                       gamma2 heavy chain chimeric (1-448) [Mus musculus VH
                                       (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6]
                                       (1-113) -Canis lupus familiaris IGHG2*02 (CH1 T26>Q
                                       (131) (114-211), hinge (212-229), CH2 (230-339), CH3
                                       (340-446), CHS (447-448)) (114-448)], (128-218')-disulfide
                                       with V-kappa-C-lambda light chain chimeric (1'-219') [Mus
                                       musculus V-KAPPA (Mus musculus IGKV8-30*01 -
                                       IGKJ5*01) [12.3.9] (1'-112') -Canis lupus familiaris
                                       IGL1CS1*01 V45.3>I (162) (114'-219')]; dimer (225-
                                       225'':228-228'')-bisdisulfide


 blontuvetmab                          immunoglobuline G2_V-kappa-C-lambda, anti-[Homo
                                       sapiens MS4A1 (membre 1 de la sous-famille A à 4
                                       domaines transmembranaires, CD20)], anticorps
                                       monoclonal caninisé;
                                       chaîne lourde gamma2 chimérique (1-448) [Mus musculus
                                       VH (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03)
                                       [8.8.6] (1-113) -Canis lupus familiaris IGHG2*02 (CH1
                                       T26>Q (131) (114-211), charnière (212-229), CH2 (230-
                                       339), CH3 (340-446), CHS (447-448)) (114-448)], (128-
                                       218')-disulfure avec la chaîne légère V-kappa-C-lambda
                                       chimérique (1'-219') [Mus musculus V-KAPPA (Mus
                                       musculus IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -
                                       Canis lupus familiaris IGL1CS1*01 V45.3>I (162) (114'-
                                       219')]; dimère (225-225'':228-228'')-bisdisulfure


 blontuvetmab                          inmunoglobulina G2_V-kappa-C-lambda, anti-[Homo
                                       sapiens MS4A1 (miembro 1 de la subfamilia A con 4
                                       dominios transmembranarios, CD20)], anticuerpo
                                       monoclonal caninizado;
                                       cadena pesada gamma2 quimérica (1-448) [Mus musculus
                                       VH (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03)
                                       [8.8.6] (1-113) -Canis lupus familiaris IGHG2*02 (CH1
                                       T26>Q (131) (114-211), bisagra (212-229), CH2 (230-339),
                                       CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-
                                       disulfuro con la cadena ligera V-kappa-C-lambda
                                       quimérica (1'-219') [Mus musculus V-KAPPA (Mus
                                       musculus IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -
                                       Canis lupus familiaris IGL1CS1*01 V45.3>I (162) (114'-
                                       219')]; dímero (225-225'':228-228'')-bisdisulfuro




                                                                                             483
Recommended INN: List 76             WHO Drug Information, Vol. 30, No. 3, 2016




 brimapitidum
 brimapitide               D-α-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-
                           D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-
                           D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-
                           D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-
                           D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-
                           D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

 brimapitide               D-α-aspartyl-D-glutaminyl-D-séryl-D-arginyl-D-prolyl-D-valyl-
                           D-glutaminyl-D-prolyl-D-phénylalanyl-D-leucyl-
                           D-asparaginyl-D-leucyl-D-thréonyl-D-thréonyl-
                           D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-
                           D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-
                           D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

 brimapitida               D-α-aspartil-D-glutaminil-D-seril-D-arginil-D-prolil-
                           D-valil-D-glutaminil-D-prolil-D-fenilalanil-D-leucil-
                           D-asparaginil-D-leucil-D-treonil-D-treonil-D-prolil-
                           D-arginil-D-lisil-D-prolil-D-arginil-D-prolil-D-prolil-
                           D-arginil-D-arginil-D-arginil-D-glutaminil-D-arginil-
                           D-arginil-D-lisil-D-lisil-D-arginilglicinamida

                           C164H286N66O40

                           D-Aminoacids sequence / Séquence      des D-aminoacides /
                           Secuencia de D-aminoácidos
                             DQSRPVQPFL         NLTTPRKPRP         PRRRQRRKKR          G   31
                           Modified residue / Résidu modifié / Resto modificado
                            G = glycinamide




484
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76




 cabiralizumabum #
 cabiralizumab                         immunoglobulin G4-kappa, anti-[Homo sapiens CSF1R
                                       (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R,
                                       macrophage colony-stimulating factor 1 receptor, c-fms,
                                       FMS, CD115)], humanized monoclonal antibody;
                                       gamma4 heavy chain (1-449) [humanized VH (Homo
                                       sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01)
                                       [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), hinge S10>P
                                       (230) (221-232), CH2 (233-342), CH3 (343-447), CHS
                                       (448-449)) (123-449)], (136-218')-disulfide with kappa light
                                       chain (1’-218’) [humanized V-KAPPA (Homo sapiens
                                       IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') -
                                       Homo sapiens IGKC*01, Km3 (112'-218')]; dimer (228-
                                       228":231-231")-bisdisulfide


 cabiralizumab                         immunoglobuline G4-kappa, anti-[Homo sapiens CSF1R
                                       (récepteur du facteur 1 stimulant de colonies, CSF-1R,
                                       CSF-1-R, récepteur du facteur 1 stimulant des colonies de
                                       macrophages, c-fms, FMS, CD115)], anticorps monoclonal
                                       humanisé;
                                       chaîne lourde gamma4 (1-449) [VH humanisé (Homo
                                       sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01)
                                       [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), charnière
                                       S10>P (230) (221-232), CH2 (233-342), CH3 (343-447),
                                       CHS (448-449)) (123-449)], (136-218')-disulfure avec la
                                       chaîne légère kappa (1’-218’) [V-KAPPA humanisé (Homo
                                       sapiens IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-
                                       111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimère
                                       (228-228":231-231")-bisdisulfure


 cabiralizumab                         inmunoglobulina G4-kappa, anti-[Homo sapiens CSF1R
                                       (receptor del factor 1 de estimulación de colonias, CSF-
                                       1R, CSF-1-R, receptor del factor 1 de estimulación de
                                       colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo
                                       monoclonal humanizado;
                                       cadena pesada gamma4 (1-449) [VH humanizado (Homo
                                       sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01)
                                       [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), bisagra
                                       S10>P (230) (221-232), CH2 (233-342), CH3 (343-447),
                                       CHS (448-449)) (123-449)], (136-218')-disulfuro con la
                                       cadena ligera kappa (1’-218’) [V-KAPPA humanizado
                                       (Homo sapiens IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9]
                                       (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')];
                                       dímero (228-228":231-231")-bisdisulfuro




                                                                                               485
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016




                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGSSVKV SCKASGYTFT                  DNYMIWVRQA       PGQGLEWMGD        50
                           INPYNGGTTF NQKFKGRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARES       100
                           PYFSNLYVMD YWGQGTLVTV SSASTKGPSV                  FPLAPCSRST       SESTAALGCL       150
                           VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                           KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP                  CPAPEFLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY                  VDGVEVHNAK       TKPREEQFNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL                  PSSIEKTISK       AKGQPREPQV       350
                           YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM                  HEALHNHYTQ       KSLSLSLGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAT LSCKASQSVD                  YDGDNYMNWY       QQKPGQAPRL 50
                           LIYAASNLES GIPARFSGSG SGTDFTLTIS                  SLEPEDFAVY       YCHLSNEDLS 100
                           TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                           QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                           THQGLSSPVT KSFNRGEC                                                           218

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          149-205       263-323   369-427
                                                 22''-96'' 149''-205'' 263''-323'' 369''-427''
                           Intra-L (C23-C104) 23'-92'        138'-198'
                                                 23'''-92''' 138'''-198'''
                           Inter-H-L (CH1 10-CL 126)         136-218' 136''-218'''
                           Inter-H-H (h 8, h 11)             228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           299, 299''
                           Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                           complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 carotuximabum #
 carotuximab               immunoglobulin G1-kappa, anti-[Homo sapiens ENG
                           (endoglin, Osler-Rendu-Weber syndrome 1, ORW1, ORW,
                           HHT1, CD105)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-448) [Mus musculus VH (IGHV6-
                           6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo sapiens
                           IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2
                           (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                           (221-213')-disulfide with kappa light chain (1'-213')
                           [chimeric V-KAPPA (Mus musculus IGKV4-72*01 -Homo
                           sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo sapiens
                           IGKC*01, Km3 (107'-213')]; dimer (227-227'':230-230'')-
                           bisdisulfide

 carotuximab               immunoglobuline G1-kappa, anti-[Homo sapiens ENG
                           (endogline, syndrome 1 d’Osler-Rendu-Weber, ORW1,
                           ORW, HHT1, CD105)], anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-448) [Mus musculus VH
                           (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo
                           sapiens IGHG1*01, Gm17,1 (CH1 (119-216), charnière
                           (217-231), CH2 (232-341), CH3 (342-446), CHS (447-
                           448)) (119-448)], (221-213')-disulfure avec la chaîne légère
                           kappa (1'-213')
                           [V-KAPPA chimérique (Mus musculus IGKV4-72*01 -
                           Homo sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo sapiens
                           IGKC*01, Km3 (107'-213')]; dimère (227-227'':230-230'')-
                           bisdisulfure

 carotuximab               inmunoglobulina G1-kappa, anti-[Homo sapiens ENG
                           (endoglina, síndrome 1 de Osler-Rendu-Weber, ORW1,
                           ORW, HHT1, CD105)], anticuerpo monoclonal quimérico;




486
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76




                                       cadena pesada gamma1 (1-448) [Mus musculus VH
                                       (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-
                                       231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                                       (119-448)], (221-213')-disulfuro con la cadena ligera kappa
                                       (1'-213') [V-KAPPA quimérico (Mus musculus IGKV4-
                                       72*01 -Homo sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo
                                       sapiens IGKC*01, Km3 (107'-213')]; dímero (227-227'':230-
                                       230'')-bisdisulfuro




 cefiderocolum
 cefiderocol                           (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-
                                       carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2-
                                       chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-
                                       1-yl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
                                       2-carboxylate

 céfidérocol                           (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-
                                       carboxypropan-2-yl)oxy]imino}acétamido]-3-({1-[2-(2-
                                       chloro-3,4-dihydroxybenzamido)éthyl]pyrrolidin-1-ium-
                                       1-yl}méthyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-
                                       2-carboxylate

 cefiderocol                           (6R,7R)-7-[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[(2-
                                       carboxipropan-2-il)oxi]imino}acetamido]-3-({1-[2-(2-cloro-
                                       3,4-dihidroxibenzamido)etil]pirrolidin-1-ium-1-il}metil)-
                                       8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-ene-2-carboxilato




                                                                                                 487
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


                           C30H34ClN7O10S2




 cemdisiranum
 cemdisiran                duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-
                           galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-
                           deoxy-β-D-galactopyranosyl)oxy]pentanamido}
                           propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-
                           oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-
                           2-yl]methyl hydrogen all-P-ambo-2'-O-methyl-P-
                           thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-
                           deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methylcytidylyl-
                           (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-
                           methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-
                           2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-
                           (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-
                           fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-
                           2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-
                           O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-
                           2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-
                           O-methyl-3'-adenylate and all-P-ambo-thymidylyl-(5'→3')-
                           thymidylyl-(5'→3')-2'-O-methyl-P-thiouridylyl-(5'→3')-2'-O-
                           methyl-P-thiouridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-
                           O-methyluridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-
                           2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-O-methyluridylyl-
                           (5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-
                           methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-
                           2'-O-methyladenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-
                           2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-
                           (5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-
                           fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-
                           methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-
                           2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiouridylyl-
                           (5'→3')-2'-deoxy-2'-fluoro-P-thioadenylyl-(5'→3')-2'-O-
                           methyluridine

 cemdisiran                duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl-
                           P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-
                           2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-méthylcytidylyl-
                           (3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-
                           méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-
                           2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                           (3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-
                           2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-
                           2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl-
                           (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-
                           2'-fluoroadénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-
                           2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthyladénylyl-
                           (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyl-3'-
                           adénylate de




488
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




                                       [(2S,4R)-1-{1-[(2-acétamido-2-déoxy-β-D-
                                       galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-
                                       2-déoxy-β-D-galactopyranosyl)oxy]pentanamido}
                                       propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-
                                       oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-
                                       2-yl]méthyle et de tout-P-ambo-thymidylyl-(5'→3')-
                                       thymidylyl-(5'→3')-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O-
                                       méthyl-P-thiouridylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-
                                       O-méthyluridylyl-(5'→3')-2'-O-méthylcytidylyl-(5'→3')-
                                       2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-O-méthyluridylyl-
                                       (5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-
                                       méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-
                                       2'-O-méthyladénylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-
                                       2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-
                                       (5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-déoxy-
                                       2'-fluoroadénylyl-(5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-O-
                                       méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-
                                       2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoro-P-thiouridylyl-
                                       (5'→3')-2'-déoxy-2'-fluoro-P-thioadénylyl-(5'→3')-2'-O-
                                       méthyluridine


 cemdisirán                            dúplex del hidrógeno-todo-P-ambo-2'-O-metil-
                                       P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-
                                       2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-
                                       2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-
                                       2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-
                                       2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-
                                       (3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil-
                                       (3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil-
                                       (3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-
                                       (3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-
                                       (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-
                                       2'-O-metil-3'-adenilato de [(2S,4R)-1-{1-[(2-acetamido-
                                       2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-
                                       acetamido-2-desoxi-β-D-
                                       galactopiranosil)oxi]pentanamido}propil)amino]-
                                       3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-
                                       triazanonacosan-29-oil}-4-hidroxipirrolidín-2-yl]metil y de
                                       todo-P-ambo-timidilil-(5'→3')-timidilil-(5'→3')-
                                       2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil-P-tiouridilil-(5'→3')-
                                       2'-O-metiluridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O-
                                       metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-O-
                                       metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-
                                       metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-
                                       metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O-
                                       metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-
                                       metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-
                                       metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-
                                       2'-fluoroadenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-
                                       2'-fluoro-P-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil-
                                       (5'→3')-2'-O-metiluridina




                                                                                                    489
Recommended INN: List 76                  WHO Drug Information, Vol. 30, No. 3, 2016




                                 C542H711F17N169O330P45S6




 clivatuzumabum tetraxetanum #
 clivatuzumab tetraxetan         immunoglobulin G1-kappa, anti-[Homo sapiens MUC1
                                 (mucin 1, polymorphic epithelial mucin, PEM, CD227)],
                                 humanized monoclonal antibody, tetraxetan conjugate;
                                 gamma1 heavy chain (1-449) [humanized VH (Homo
                                 sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12]
                                 (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217),
                                 (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S
                                 (448-449)) (120-449)], (222-215')-disulfide with kappa light
                                 chain (1'-215') [humanized V-KAPPA (Homo sapiens
                                 IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo
                                 sapiens IGKC*01 (109'-215')]; (228-228":231-231")-
                                 bisdisulfide dimer; tetraxetan (DOTA) conjugate (on an
                                                                                           6
                                 average of 4 to 7 lysyl, linked to the chelator by their N )

 clivatuzumab tétraxétan         immunoglobuline G1-kappa, anti-[Homo sapiens MUC1
                                 (mucine 1, mucine épithéliale polymorphique, PEM,
                                 CD227)], anticorps monoclonal humanisé, conjugué au
                                 tétraxétan;
                                 chaîne lourde gamma1 (1-449) [VH humanisé (Homo
                                 sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12]
                                 (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217),
                                 (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S
                                 (448-449)) (120-449)], (222-215')-disulfure avec la chaîne
                                 légère kappa (1'-215') [V-KAPPA humanisé (Homo sapiens
                                 IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo
                                 sapiens IGKC*01 (109'-215')]; dimère (228-228":231-231")-
                                 bisdisulfure; conjugué au tétraxétan (DOTA) (avec une
                                                                                     6
                                 moyenne de 4 à 7 lysyl liés au chélateur par leur N )

 clivatuzumab tetraxetán         inmunoglobulina G1-kappa, anti-[Homo sapiens MUC1
                                 (mucina 1, mucina epitelial polimórfica, PEM, CD227)],
                                 anticuerpo monoclonal humanizado, conjugado con
                                 tetraxetán;




490
WHO Drug Information, Vol. 30, No. 3, 2016                                             Recommended INN: List 76




                                       cadena pesada gamma1 (1-449) [VH humanizado (Homo
                                       sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12]
                                       (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217),
                                       (bisagra 218-232), CH2 (233-342), CH3 (343-447), CH-S
                                       (448-449)) (120-449)], (222-215')-disulfuro con la cadena
                                       ligera kappa (1'-215') [V-KAPPA humanizado (Homo
                                       sapiens IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108')
                                       -Homo sapiens IGKC*01 (109'-215')]; dímero (228-
                                       228":231-231")-bisdisulfuro; conjugado con tetraxetán
                                       (DOTA) (con una media de 4 a 7 restos lisil unidos al
                                                                      6
                                       quelante por sus respectivos N )


                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLQQSGAE VKKPGASVKV SCEASGYTFP                          SYVLHWVKQA    PGQGLEWIGY         50
                                       INPYNDGTQY NEKFKGKATL TRDTSINTAY                          MELSRLRSDD    TAVYYCARGF        100
                                       GGSYGFAYWG QGTLVTVSSA STKGPSVFPL                          APSSKSTSGG    TAALGCLVKD        150
                                       YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                          LYSLSSVVTV    PSSSLGTQTY        200
                                       ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                          CPAPELLGGP    SVFLFPPKPK        250
                                       DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                          VDGVEVHNAK    TKPREEQYNS        300
                                       TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                          PAPIEKTISK    AKGQPREPQV        350
                                       YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                          VEWESNGQPE    NNYKTTPPVL        400
                                       DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                          HEALHNHYTQ    KSLSLSPGK         449

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQLTQSPSS LSASVGDRVT MTCSASSSVS                          SSYLYWYQQK    PGKAPKLWIY 50
                                       STSNLASGVP ARFSGSGSGT DFTLTISSLQ                          PEDSASYFCH    QWNRYPYTFG 100
                                       GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT                          ASVVCLLNNF    YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                          TLSKADYEKH    KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                                   215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96         146-202       263-323  369-427
                                                             22''-96'' 146''-202'' 263''-323'' 369''-427''
                                       Intra-L (C23-C104) 23'-89' 135'-195'
                                                            23'''-89''' 135'''-195'''
                                       Inter-H-L (h 5-CL 126) 222-215' 222''-215'''
                                       Inter-H-H (h 11, h 14) 228-228'' 231-231''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       299, 299''
                                       Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires
                                       complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

                                       Modified residues / Résidus modifies / Restos modificados
                                             4 to 7 lysyl (K)                               NH
                                             4 à 7 lysyl (K)                                                        CO2H
                                              4 a 7 lisil (K)                               O          N      N
                                                                                  H

                                         N6-(tetraxetan)-L-lysyl
                                                                           N       C
                                                                           H                           N      N
                                                                                   O       HO2C                     CO2H




 crotedumabum #
 crotedumab                            immunoglobulin G4-kappa, anti-[Homo sapiens GCGR
                                       (glucagon receptor)], Homo sapiens monoclonal antibody;
                                       gamma4 heavy chain (1-455) [Homo sapiens VH (IGHV3-
                                       7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) -
                                       IGHG4*01 (CH1 (129-226), hinge S10>P (236) (227-238),
                                       CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-
                                       455)], (142-214')-disulfide with kappa light chain (1’-214’)
                                       [Homo sapiens (V-KAPPA (IGKV1-17*01 (95.80%) -
                                       IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')];
                                       dimer (234-234":237-237")-bisdisulfide




                                                                                                                                     491
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


 crotédumab                immunoglobuline G4-kappa, anti-[Homo sapiens GCGR
                           (récepteur du glucagon)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma4 (1-455) [Homo sapiens VH
                           (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-
                           128) -IGHG4*01 (CH1 (129-226), charnière S10>P (236)
                           (227-238), CH2 (239-348), CH3 (349-453), CHS (454-
                           455)) (129-455)], (142-214')-disulfure avec la chaîne légère
                           kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-17*01
                           (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dimère (234-234":237-237")-bisdisulfure

 crotedumab                inmunoglobulina G4-kappa, anti-[Homo sapiens GCGR
                           (receptor de glucagón)], Homo sapiens anticuerpo
                           monoclonal;
                           cadena pesada gamma4 (1-455) [Homo sapiens VH
                           (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-
                           128) -IGHG4*01 (CH1 (129-226), bisagra S10>P (236)
                           (227-238), CH2 (239-348), CH3 (349-453), CHS (454-
                           455)) (129-455)], (142-214')-disulfuro con la cadena ligera
                           kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-17*01
                           (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dímero (234-234":237-237")-bisdisulfuro




 dapansutrilum
 dapansutrile              3-(methanesulfonyl)propanenitrile

 dapansutrile              3-(méthanesulfonyl)propanenitrile

 dapansutrilo              3-(metanosulfonil)propanonitrilo




492
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76


                                       C4H7NO2S




 deudextromethorphanum
                                             2                 2
 deudextromethorphan                   3-[( H3)methoxy]-17-[( H3)methyl]-ent-morphinan
                                             2                 2
 deudextromethorphane                  3-[( H3)méthoxy]-17-[( H3)méthyl]-ent-morphinane
                                             2             2
 deudextrometorfano                    3-[( H3)metoxi]-17-[( H3)metil]-ent-morfinano
                                                 2
                                       C18H19 H6NO




 dociparstatum natricum
 dociparstat sodium                    sodium salt of 2,3-di-O-desulfoheparin, the starting
                                       material is an unfractionated heparin from porcine
                                       intestinal mucosa, the relative average molecular mass is
                                       approximately 12,000 daltons with about 40% ranging
                                       between 8,000 and 16,000 daltons, the degree of sulfation
                                       is about 2.0 per disaccharidic unit

 dociparstat sodique                   sel de sodium de la 2,3-di-O-désulfohéparine, obtenu à
                                       partir d’héparine non-fractionnée de la muqueuse
                                       intestinale porcine; sa masse moléculaire relative dont
                                       environ 40% est comprise entre 8.000 et 16.000 daltons,
                                       est voisine de 12.000 daltons; son degré de sulfatation est
                                       d’environ 2,0 par unité disaccharide

 dociparstat sodico                    sal de sodio de la 2,3-di-O-desulfoheparina, obtenida a
                                       partir de la heparina no fraccionad de la mucosa intestinal
                                       porcina; la masa molecular relativa media es
                                       aproximadamente de 12000 daltons con el 40%
                                       comprendido entre 8000 y 16000 daltons; el grado de
                                       sulfatación es de 2,0 por unidad de disacárido.




                                                                                               493
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


 dolcanatidum
 dolcanatide               1D,16D-[3-L-glutamic acid]human uroguanylin:
                              4  12  7 15
                            S ,S :S ,S -dicyclo(D-asparaginyl-L-α-aspartyl-
                           L-α-glutamyl-L-cysteinyl-L-α-glut-amyl-L-leucyl-L-cysteinyl-
                           L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-
                           L-threonylglycyl-L-cysteinyl-D-leucine)

 dolcanatide               1D,16D-[3-acide L-glutamique]uroguanyline humaine:
                              4  12  7 15
                            S ,S :S ,S -dicyclo(D-asparaginyl-L-α-aspartyl
                           -L-α-glutamyl-L-cystéinyl-L-α-glut-amyl-L-leucyl-L-cystéinyl-
                           L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cystéinyl-
                           L-thréonylglycyl-L-cystéinyl-D-leucine)

 dolcanatida               1D,16D-[3-L-ácido glutámico]uroguanilina humana:
                             4  12  7   15
                           S ,S :S ,S -diciclo(D-asparaginil-L-α-aspartil-L-α-glutamil-
                           L-cisteinil-L-α-glut-amil-L-leucil-L-cisteinil-L-valil-
                           L-asparaginil-L-valil-L-alanil-L-cisteinil-L-treonilglicil-
                           L-cisteinil-D-leucina)

                           C65H104N18O26S4




 domagrozumabum #
 domagrozumab              immunoglobulin G1-kappa, anti-[Homo sapiens MSTN
                           (growth differentiation factor 8, GDF8, myostatin,GDF-8)],
                           humanized monoclonal antibody;
                           gamma1 heavy chain (1-446) [humanized VH (Homo
                           sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9]
                           (1-116) -IGHG1*01 (CH1 (117-214), hinge (215-229), CH2
                           L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3
                           D12>E (355), L14>M (357) (340-444), CHS (445-446))
                           (117-446)], (219-214')-disulfide with kappa light chain (1’-
                           214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01
                           (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-
                           bisdisulfide


 domagrozumab              immunoglobuline G1-kappa, anti-[Homo sapiens MSTN
                           (facteur de croissance et de différenciation 8, GDF8,
                           myostatine, GDF-8)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-446) [VH humanisé (Homo
                           sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9]
                           (1-116) -IGHG1*01, G1m17,1 (CH1 (117-214), charnière
                           (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236)
                           (230-339), CH3 D12>E (355), L14>M (357) (340-444),
                           CHS (445-446)) (117-446)], (219-214')- disulfure avec la
                           chaîne légère (1’-214’) [V-KAPPA humanisé (Homo
                           sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107')
                           -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (225-
                           225":228-228")-bisdisulfure




494
WHO Drug Information, Vol. 30, No. 3, 2016                                        Recommended INN: List 76


 domagrozumab                          inmunoglobulina G1-kappa, anti-[Homo sapiens MSTN
                                       (factor de crecimiento y de diferenciación 8, GDF8,
                                       miostatina, GDF-8)], anticuerpo monoclonal humanizado;
                                       cadena pesada gamma1 (1-446) [VH humanizado (Homo
                                       sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9]
                                       (1-116) -IGHG1*01 (CH1 (117-214), bisagra (215-229),
                                       CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339),
                                       CH3 D12>E (355), L14>M (357) (340-444), CHS (445-
                                       446)) (117-446)], (219-214')-disulfuro con la cadena ligera
                                       kappa (1’-214’) [V-KAPPA humanizado (Homo sapiens
                                       IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo
                                       sapiens IGKC*01, Km3 (108'-214')]; dímero (225-225":228-
                                       228")-bisdisulfuro

                                        Heavy chain / Chaîne lourde / Cadena pesada
                                        EVQLLESGGG LVQPGGSLRL SCAASGFTFS                  SYAMSWVRQA       PGKGLEWVST        50
                                        ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCAKQD       100
                                        YAMNYWGQGT LVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                                        EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                                        VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PEAAGAPSVF       LFPPKPKDTL       250
                                        MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                                        VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                                        PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                        GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                        Light chain / Chaîne légère / Cadena ligera
                                        DIQMTQSPSS LSASVGDRVT ITCKASQDVS                  TAVAWYQQKP       GKAPKLLIYS 50
                                        ASYRYTGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       HYSTPWTFGG 100
                                        GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                        DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                        LSSPVTKSFN RGEC                                                               214

                                        Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                        Intra-H (C23-C104) 22-96          143-199       260-320  366-424
                                                              22''-96'' 143''-199'' 260''-320'' 366''-424''
                                        Intra-L (C23-C104) 23'-88'         134'-194'
                                                              23'''-88''' 134'''-194'''
                                        Inter-H-L (h 5-CL 126) 219-214' 219''-214'''
                                        Inter-H-H (h 11, h 14) 225-225'' 228-228''

                                        N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                        H CH2 N84.4:
                                        296, 296''
                                        Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                        complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
                                        Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                                        modificaciones post-traduccionales
                                        C-terminal trimming of the C-terminal lysine (K)
                                        H CHS K2:
                                        446, 446''


 edasalonexentum
 edasalonexent                         N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-
                                       hexaenamido]ethyl}-2-hydroxybenzamide

 édasalonexent                         N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-
                                       hexaénamido]éthyl}-2-hydroxybenzamide

 edasalonexento                        N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-
                                       hexaenamido]etil}-2-hidroxibenzamida

                                       C28H39N3O2




                                                                                                                               495
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 edonerpicum
 edonerpic                 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol

 édonerpic                 1-{3-[2-(1-benzothiophén-5-yl)éthoxy]propyl}azétidin-3-ol

 edonerpico                1-{3-[2-(1-benzotiofen-5-il)etoxi]propil}azetidin-3-ol

                           C16H21NO2S




 enoblituzumabum #
 enoblituzumab             immunoglobulin G1-kappa, anti-[Homo sapiens CD276
                           (B7H3, B7-H3, B7RP-2)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-452) [humanized VH (Homo
                           sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01)
                           [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123-
                           220), hinge (221-235), CH2 L1.2>V (240), F7>L (248),
                           R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401)
                           (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide
                           with kappa light chain (1’-214’) [humanized V-KAPPA
                           (Homo sapiens IGKV1D-13*01 (85.10%) -IGKJ2*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           dimer (231-231":234-234")-bisdisulfide

 énoblituzumab             immunoglobuline G1-kappa, anti-[Homo sapiens CD276
                           (B7H3, B7-H3, B7RP-2)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-452) [VH humanisé (Homo
                           sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01)
                           [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123-
                           220), charnière (221-235), CH2 L1.2>V (240), F7>L (248),
                           R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401)
                           (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure
                           avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé
                           (Homo sapiens IGKV1D-13*01 (85.10%) -IGKJ2*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')];
                           dimère (231-231":234-234")-bisdisulfure

 enoblituzumab             inmunoglobulina G1-kappa, anti-[Homo sapiens CD276
                           (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma1 (1-452) [VH humanizado (Homo
                           sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01)
                           [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123-
                           220), bisagra (221-235), CH2 L1.2>V (240), F7>L (248),
                           R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401)
                           (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro
                           con la cadena ligera kappa (1’-214’) [V-KAPPA
                           humanizado (Homo sapiens IGKV1D-13*01 (85.10%) -
                           IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                           (108'-214')]; dímero (231-231":234-234")-bisdisulfuro




496
WHO Drug Information, Vol. 30, No. 3, 2016                                        Recommended INN: List 76




                                        Heavy chain / Chaîne lourde / Cadena pesada
                                        QVELVESGGG LVQPGGSLRL SCAASGFTFT                  SYWMSWVRQA       PGKGLELVSS        50
                                        ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARNM       100
                                        YTHFDSWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                        PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                        NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                                        LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                        RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                                        LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                        DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                        Light chain / Chaîne légère / Cadena ligera
                                        DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG                  SNSVSWYQQL       PGTAPKLLIY 50
                                        DNSKRPSGVP DRFSGSKSGT SASLAITGLQ                  SEDEADYYCQ       SRDTYGYYWV 100
                                        FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ                  ANKATLVCLI       SDFYPGAVTV 150
                                        AWKGDSSPVK AGVETTTPSK QSNNKYAASS                  YLSLTPEQWK       SHRSYSCQVT 200
                                        HEGSTVEKTV APTECS                                                             216

                                        Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                        Intra-H (C23-C104)        22-96       144-200       261-321   367-425
                                                                  22''-96'' 144''-200'' 261''-321'' 367''-425''
                                        Intra-L (C23-C104)        22'-89'     138'-197'
                                                                  22'''-89''' 138'''-197'''
                                        Inter-H-L (h 5-CL 126) 220-215' 220''-215'''
                                        Inter-H-H (h 11, h 14) 226-226' 229-229''

                                        N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                        H CH2 N84.4:
                                        297, 297''
                                        Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                        complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


 epacadostatum
 epacadostat                           (Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-
                                       4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole-
                                       3-carboximidamide

 épacadostat                           (Z)-N-(3-bromo-4-fluorophényl)-N'-hydroxy-
                                       4-{[2-(sulfamoylamino)éthyl]amino}-1,2,5-oxadiazole-
                                       3-carboximidamide

 epacadostat                           (Z)-N-(3-bromo-4-fluorofenil)-N'-hidroxi-
                                       4-{[2-(sulfamoilamino)etil]amino}-1,2,5-oxadiazol-
                                       3-carboximidamida

                                       C11H13BrFN7O4S




 esaxerenonum
 esaxerenone                           (5P)-1-(2-hydroxyethyl)-N-[4-(methanesulfonyl)phenyl]-
                                       4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-
                                       3-carboxamide

 ésaxérénone                           (5P)-1-(2-hydroxyéthyl)-N-[4-(méthanesulfonyl)phényl]-
                                       4-méthyl-5-[2-(trifluorométhyl)phényl]-1H-pyrrole-
                                       3-carboxamide

 esaxerenona                           (5P)-1-(2-hidroxietil)-N-[4-(metanosulfonil)fenil]-4-metil-
                                       5-[2-(trifluorometil)fenil]-1H-pirrol-3-carboxamida




                                                                                                                                497
Recommended INN: List 76                   WHO Drug Information, Vol. 30, No. 3, 2016



                           C22H21F3N2O4S




 fexapotidum
 fexapotide                L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-
                           L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-
                           L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-
                           L-leucine

 fexapotide                L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-
                           L-leucyl-L-séryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-
                           L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cystéinyl-
                           L-leucine

 fexapotida                L-isoleucil-L-α-aspartil-L-glutaminil-L-glutaminil-L-valil-
                           L-leucil-L-seril-L-arginil-L-isoleucil-L-lisil-L-leucil-L-α-glutamil-
                           L-isoleucil-L-lisil-L-arginil-L-cisteinil-L-leucina

                           C90H163N27O25S




                     18
 flortaucipirum ( F)
               18                18
 flortaucipir ( F)         7-[6-( F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indole
              18                 18
 flortaucipir ( F)         7-[6-( F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indole
              18                 18
 flortaucipir ( F)         7-[6-( F)fluoropiridin-3-il]-5H-pirido[4,3-b]indol
                                      18
                           C16H10 FN3




 fonadelparum
 fonadelpar                {[5-methyl-3-(2-{4-(propan-2-yl)-
                           2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)-
                           1,2-benzoxazol-6-yl]oxy}acetic acid




498
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




 fonadelpar                            acide {[5-méthyl-3-(2-{4-(propan-2-yl)-
                                       2-[4-(trifluorométhyl)phényl]-1,3-thiazol-5-yl}éthyl)-
                                       1,2-benzoxazol-6-yl]oxy}acétique

 fonadelpar                            ácido {[5-metil-3-(2-{4-(propan-2-il)-
                                       2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}etil)-1,2-benzoxazol-
                                       6-il]oxi}acético

                                       C25H23F3N2O4S




 galcanezumabum #
 galcanezumab                          immunoglobulin G4-kappa, anti-[Homo sapiens CALCA
                                       (calcitonin-related polypeptide alpha, calcitonin 1, CALC1)
                                       and Homo sapiens CALCB (calcitonin-related polypeptide
                                       beta, calcitonin 2, CALC2)], humanized monoclonal
                                       antibody;
                                       gamma4 heavy chain (1-445) [humanized VH (Homo
                                       sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01)
                                       [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), hinge S10>P
                                       (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-
                                       339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-
                                       214')-disulfide with kappa light chain (1’-214’) [humanized
                                       V-KAPPA (Homo sapiens IGKV1-39*01 (87.40%) -
                                       IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                       (108'-214')]; dimer (225-225":228-228")-bisdisulfide

 galcanézumab                          immunoglobuline G4-kappa, anti-[Homo sapiens CALCA
                                       (polypeptide alpha apparenté à la calcitonine, calcitonine
                                       1, CALC1) et Homo sapiens CALCB (polypeptide beta
                                       apparenté à la calcitonine, calcitonine 2, CALC2)],
                                       anticorps monoclonal humanisé;
                                       chaîne lourde gamma4 (1-445) [VH humanisé (Homo
                                       sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01)
                                       [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), charnière
                                       S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234)
                                       (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)],
                                       (133-214')-disulfure avec la chaîne légère kappa (1’-214’)
                                       [V-KAPPA humanisé (Homo sapiens IGKV1-39*01
                                       (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")
                                       bisdisulfure




                                                                                                    499
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016


 galcanezumab              inmunoglobulina G4-kappa, anti-[Homo sapiens CALCA
                           (polipéptido alfa relacionado con la calcitonina, calcitonina
                           1, CALC1) y Homo sapiens CALCB (polipéptido beta
                           relacionado con la calcitonina, calcitonina 2, CALC2)],
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-445) [VH humanizado (Homo
                           sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01)
                           [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), bisagra
                           S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234)
                           (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)],
                           (133-214')-disulfuro con la cadena ligera kappa (1’-214’)
                           [V-KAPPA humanizado (Homo sapiens IGKV1-39*01
                           (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-
                           bisdisulfuro

                            Heavy chain / Chaîne lourde / Cadena pesada
                            QVQLVQSGAE VKKPGSSVKV SCKASGYTFG                  NYWMQWVRQA       PGQGLEWMGA        50
                            IYEGTGKTVY IQKFADRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARLS       100
                            DYVSGFGYWG QGTTVTVSSA STKGPSVFPL                  APCSRSTSES       TAALGCLVKD       150
                            YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTKTY       200
                            TCNVDHKPSN TKVDKRVESK YGPPCPPCPA                  PEAAGGPSVF       LFPPKPKDTL       250
                            MISRTPEVTC VVVDVSQEDP EVQFNWYVDG                  VEVHNAKTKP       REEQFNSTYR       300
                            VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS                  IEKTISKAKG       QPREPQVYTL       350
                            PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                            GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA                  LHNHYTQKSL       SLSLG            445

                            Light chain / Chaîne légère / Cadena ligera
                            DIQMTQSPSS LSASVGDRVT ITCRASKDIS                  KYLNWYQQKP       GKAPKLLIYY 50
                            TSGYHSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       GDALPPTFGG 100
                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                            LSSPVTKSFN RGEC                                                               214

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H (C23-C104) 22-96          146-202       260-320 366-424
                                                  22''-96'' 146''-202'' 260''-320'' 366''-424''
                            Intra-L (C23-C104) 23'-88'        134'-194'
                                                  23'''-88''' 134'''-194'''
                            Inter-H-L (CH1 10-CL 126) 133-214' 133''-214'''
                            Inter-H-H (h 8, h 11)            225-225'' 228-228''

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            296, 296''
                            Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                            complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


 galidesivirum
 galidesivir               (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
                           5-(hydroxymethyl)pyrrolidine-3,4-diol

 galidésivir               (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-
                           5-(hydroxyméthyl)pyrrolidine-3,4-diol

 galidesivir               (2S,3S,4R,5R)-2-(4-amino-5H-pirrolo[3,2-d]pirimidin-7-il)-5-
                           (hidroximetil)pirrolidina-3,4-diol

                           C11H15N5O3




500
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76




 givosiranum
 givosiran                             duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-
                                       galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-
                                       2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)
                                       amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-
                                       6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-
                                       yl]methyl hydrogen all-P-ambo-2'-O-methyl-P-thiocytidylyl-
                                       (3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-
                                       methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-
                                       methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-
                                       deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methyladenylyl-
                                       (3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-
                                       methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-
                                       O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-
                                       2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-
                                       (3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-
                                       (3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyluridylyl-
                                       (3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyl-
                                       3'-adenylate and all-P-ambo-2'-O-methyl-P-thiouridylyl-
                                       (5'→3')-2'-O-methyl-P-thioguanylyl-(5'→3')-2'-O-
                                       methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-
                                       2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-
                                       (5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-
                                       2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-
                                       2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-
                                       (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-
                                       methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-
                                       2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-
                                       (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-
                                       2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-
                                       2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-deoxy-2'-fluoro-
                                       P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thioadenylyl-
                                       (5'→3')-2'-O-methyluridine

 givosiran                             duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl-
                                       P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-
                                       2'-O-méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-
                                       2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-
                                       2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-méthyladénylyl-
                                       (3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-
                                       méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-
                                       2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-
                                       (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-
                                       fluorocytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-
                                       méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                                       méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                                       méthyl-3'-adénylate de [(2S,4R)-1-{1-[(2-acétamido-2-
                                       déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-
                                       acétamido-2-déoxy-β-D-galactopyranosyl)oxy]
                                       pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-
                                       trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-
                                       4-hydroxypyrrolidin-2-yl]méthyle et




                                                                                                501
Recommended INN: List 76             WHO Drug Information, Vol. 30, No. 3, 2016


                           du tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O-
                           méthyl-P-thioguanylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-
                           2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidylyl-
                           (5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-
                           méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-
                           O-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-
                           2'-O-méthylcytidylyl-(5'→3')-2'-déoxy-
                           2'-fluoroadénylyl-(5'→3')-2'-O-méthylcytidylyl-(5'→3')-
                           2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-
                           (5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-
                           méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-
                           2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-
                           (5'→3')-2'-déoxy-2'-fluoro-P-thioadénylyl-(5'→3')-2'-déoxy-
                           2'-fluoro-P-thioadénylyl-(5'→3')-2'-O-méthyluridine

 givosirán                 dúplex del hidrógeno-todo-P-ambo-2'-O-metil-P-tiocitidilil-
                           (3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilguanilil-
                           (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-
                           2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-
                           2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-
                           2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-
                           2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-
                           metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                           metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                           metiluridilil-(3'→5')-2'-O-metil-3'-adenilato de [(2S,4R)-1-{1-
                           [(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-
                           bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-
                           galactopiranosil)oxi]pentanamido}propil)amino]-
                           3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-
                           triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del
                           todo-P-ambo-2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil-
                           P-tioguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-
                           2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-
                           2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-
                           2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-
                           2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-
                           2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-
                           2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-
                           2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-
                           2'-fluorouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-
                           2'-fluoroguanilil-(5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil-
                           (5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil-(5'→3')-2'-O-
                           metiluridina


                           C524H694F16N173O316P43S6




502
WHO Drug Information, Vol. 30, No. 3, 2016                          Recommended INN: List 76




 glecaprevirum
 glecaprevir                           (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-
                                       2-(difluoromethyl)-1-[(1-methylcyclopropane-
                                       1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-
                                       2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-
                                       methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclonon
                                       adecino[11,12-b]quinoxaline-10-carboxamide

 glécaprévir                           (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-
                                       2-(difluorométhyl)-1-[(1-méthylcyclopropane-
                                       1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-
                                       2,3,3a,5,6,7,8,11,12,20,23,24a-dodécahydro-1H,10H-9,12-
                                       méthanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclonon
                                       adécino[11,12-b]quinoxaline-10-carboxamide

 glecaprevir                           (3aR,7S,10S,12R,21E,24aR)-7-tert-butil-N-{(1R,2R)-
                                       2-(difluorometil)-1-[(1-metilciclopropano-
                                       1-sulfonil)carbamoil]ciclopropil}-20,20-difluoro-5,8-dioxo-
                                       2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahidro-1H,10H-9,12-
                                       metanociclopenta[18,19][1,10,17,3,6]trioxadiazaciclononad
                                       ecino[11,12-b]quinoxalina-10-carboxamida

                                       C38H46F4N6O9S




 glesatinibum
 glesatinib                            N-[(3-fluoro-4-{[2-(5-{[(2-
                                       methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-
                                       b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-
                                       2-(4-fluorophenyl)acetamide

 glésatinib                            N-[(3-fluoro-4-{[2-(5-{[(2-
                                       méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2-
                                       b]pyridin-7-yl]oxy}phényl)carbamothioyl]-
                                       2-(4-fluorophényl)acétamide

 glesatinib                            N-[(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin-
                                       2-il)tieno[3,2-b]piridin-7-il]oxi}fenil)carbamotioil]-
                                       2-(4-fluorofenil)acetamida




                                                                                                    503
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


                           C31H27F2N5O3S2

                                             H
                                             N        S

                                                                                  CH3
                                         O       HN       F
                            F                                                 O

                                                          O

                                                                S                 NH


                                                          N           N


 inclisiranum
 inclisiran                duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-
                           galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-
                           2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}
                           propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-
                           oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-
                           2-yl]methyl hydrogen all-P-ambo-2'-O-methyl-P-
                           thiocytidylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-
                           methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                           methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-
                           deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-
                           2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methyluridylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                           methyl-3'-uridylate and all-P-ambo-2'-O-methyl-
                           P-thioadenylyl-(5'→3')-2'-O-methyl-P-thioadenylyl-(5'→3')-
                           2'-O-methylguanylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-
                           2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-
                           (5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-
                           2'-fluoroguanylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-
                           2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylcytidylyl-
                           (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-
                           methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-
                           2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-
                           (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-
                           2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-
                           (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyl-
                           P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiocytidylyl-
                           (5'→3')-2'-O-methyladenosine

 inclisiran                duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl-
                           P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-
                           2'-O-méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-
                           2'-O-méthyladénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-
                           2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthyluridylyl-
                           (3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthyl-3'-uridylate de




504
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




                                       [(2S,4R)-1-{1-[(2-acétamido-2-déoxy-
                                       β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-
                                       acétamido-2-déoxy-β-D-galactopyranosyl)oxy]
                                       pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-
                                       trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-
                                       hydroxypyrrolidin-2-yl]méthyle et du tout-P-ambo-2'-O-
                                       méthyl-P-thioadénylyl-(5'→3')-2'-O-méthyl-P-thioadénylyl-
                                       (5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthyladénylyl-
                                       (5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-
                                       fluorocytidylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-
                                       2'-fluoroguanylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-
                                       déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylcytidylyl-
                                       (5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-
                                       méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-
                                       2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-
                                       (5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-
                                       fluoroadénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-
                                       2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthyl-P-
                                       thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-P-thiocytidylyl-
                                       (5'→3')-2'-O-méthyladénosine


 inclisirán                            dúplex del hidrógeno-todo-P-ambo-2'-O-metil-P-tiocitidilil-
                                       (3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metiladenilil-
                                       (3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-
                                       2'-O-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-
                                       2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-
                                       2'-O-metiluridilil-(3'→5')-timidilil-(3'→5')-2'-O-metiluridilil-
                                       (3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-
                                       2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                                       metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                                       metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metil-
                                       3'-uridilato de [(2S,4R)-1-{1-[(2-acetamido-2-desoxi-β-D-
                                       galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-
                                       desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-
                                       3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-
                                       triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del
                                       todo-P-ambo-2'-O-metil-P-tioadenilil-(5'→3')-2'-O-metil-
                                       P-tioadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-
                                       metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-
                                       2'-fluorocitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-
                                       2'-fluoroguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-
                                       2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-
                                       2'-fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-
                                       2'-fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-
                                       2'-fluorocitidilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-
                                       2'-fluoroadenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-
                                       2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metil-P-tioadenilil-
                                       (5'→3')-2'-desoxi-2'-fluoro-P-tiocitidilil-(5'→3')-2'-O-
                                       metiladenosina

                                       C529H707F12N176O316P43S6




                                                                                                   505
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 intepirdinum
 intepirdine               3-(benzenesulfonyl)-8-(piperazin-1-yl)quinolone

 intépirdine               3-(benzènesulfonyl)-8-(pipérazin-1-yl)quinolone

 intepirdina               3-(bencenosulfonil)-8-(piperazin-1-il)quinolina

                           C19H19N3O2S




 ivosidenibum
 ivosidenib                (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-
                           difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-
                           2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-
                           2-carboxamide

 ivosidénib                (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-
                           difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-
                           2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-
                           2-carboxamide

 ivosidenib                (2S)-N-{(1S)-1-(2-clorofenil)-2-[(3,3-
                           difluorociclobutil)amino]-2-oxoetil}-1-(4-cianopiridin-2-il)-
                           N-(5-fluoropiridin-3-il)-5-oxopirrolidina-2-carboxamida

                           C28H22ClF3N6O3




506
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76




 lanadelumabum #
 lanadelumab                           immunoglobulin G1-kappa, anti-[Homo sapiens KLKB1
                                       (kallikrein B 1, plasma prekallikrein (zymogen),
                                       kininogenin, Fletcher factor) proteolytically cleaved by F12
                                       (factor FXII), active plasma kallikrein (EC 3.4.21.34)],
                                       Homo sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-
                                       23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -
                                       IGHG1*03, G1m3 (CH1 (123-220), hinge (221-235), CH2
                                       (236-345), CH3 (346-450), CHS K2>del (451))(123-451)],
                                       (225-213')-disulfide with kappa light chain (1'-213') [Homo
                                       sapiens V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01)
                                       [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (231-
                                       231'':234-234'')-bisdisulfide


 lanadélumab                           immunoglobuline G1-kappa, anti-[Homo sapiens KLKB1
                                       (kallikréine B 1, prékallikréine plasmatique (zymogène),
                                       kininogénine, facteur de Fletcher) clivé protéolytiquement
                                       par F12 (facteur FXII), kallikréine plasmatique active (EC
                                       3.4.21.34)], Homo sapiens anticorps monoclonal;
                                       chaîne lourde gamma1 (1-451) [Homo sapiens VH
                                       (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-
                                       122) -IGHG1*03, G1m3 (CH1 (123-220), charnière (221-
                                       235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))
                                       (123-451)], (225-213')-disulfure avec la chaîne légère
                                       kappa (1'-213') [Homo sapiens V-KAPPA (IGKV1-5*03
                                       (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-
                                       213')]; dimère (231-231'':234-234'')-bisdisulfure


 lanadelumab                           inmunoglobulina G1-kappa, anti-[Homo sapiens KLKB1
                                       (kalikreína B 1, prekalikreína plasmática (zimógeno),
                                       kininogenina, factor de Fletcher) dividida proteolíticamente
                                       por F12 (factor FXII), kalikreína plasmática activa (EC
                                       3.4.21.34)], Homo sapiens anticuerpo monoclonal;
                                       cadena pesada gamma1 (1-451) [Homo sapiens VH
                                       (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-
                                       122) -IGHG1*03, G1m3 (CH1 (123-220), bisagra (221-
                                       235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))
                                       (123-451)], (225-213')-disulfuro con la cadena ligera kappa
                                       (1'-213') [Homo sapiens V-KAPPA (IGKV1-5*03 (97.90%) -
                                       IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3(107'-213')];
                                       dímeo (231-231'':234-234'')-bisdisulfuro




                                                                                                507
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 laprituximabum #
 laprituximab              immunoglobulin G1-kappa, anti-[Homo sapiens EGFR
                           (epidermal growth factor receptor, receptor tyrosine-protein
                           kinase erbB-1, ERBB1, HER1, HER-1, ERBB) ], chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1-
                           7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo sapiens
                           IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2
                           (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)],
                           (222-214')-disulfide with kappa light chain (1'-214') [Mus
                           musculus V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'-
                           107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                           (228-228'':231-231'')-bisdisulfide

 laprituximab              immunoglobuline G1-kappa, anti-[Homo sapiens EGFR
                           (récepteur du facteur de croissance épidermique,
                           récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1,
                           HER-1, ERBB)], anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-448) [Mus musculus VH
                           (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01, Gm17,1 (CH1 (120-217), charnière
                           (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del
                           (448)) (120-448)], (222-214')-disulfure avec la chaîne
                           légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV19-
                           93*01 - IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01, Km3 (108'-214')]; dimère (228-228'':231-231'')-
                           bisdisulfure.

 laprituximab              inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR
                           (receptor del factor de crecimiento epidérmico, receptor
                           tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1,
                           ERBB) ], anticuerpo monoclonal quimérico;




508
WHO Drug Information, Vol. 30, No. 3, 2016                                 Recommended INN: List 76




                                       cadena pesada gamma1 (1-448) [Mus musculus VH
                                       (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-
                                       232), CH2 (233-342), CH3 (343-447), CHS K2>del (448))
                                       (120-448)], (222-214')-disulfuro con la cadena ligera kappa
                                       (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01 -
                                       IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                       (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro




 laprituximabum emtansinum #
 laprituximab emtansine                immunoglobulin G1-kappa, anti-[Homo sapiens EGFR
                                       (epidermal growth factor receptor, receptor tyrosine-protein
                                       kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric
                                       monoclonal antibody conjugated to maytansinoid DM1;
                                       gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1-
                                       7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens
                                       IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2
                                       (233-342), CH3 (343-447), CHS K2>del (448) (120-448)],
                                       (222-214')-disulfide with kappa light chain (1'-214') [Mus
                                       musculus V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9]
                                       (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                                       (228-228'':231-231'')-bisdisulfide; conjugated, on an
                                       average of 3 to 4 lysyl, to maytansinoid DM1 via a
                                       succinimidyl-4-(N-maleimidomethyl) cyclohexane-
                                       1-carboxylate (SMCC) linker forming a nonreducible
                                       thioether bond
                                       For the emtansine part, please refer to the document ''INN for pharmaceutical
                                       substances: Names for radicals, groups and others''*.


 laprituximab emtansine                immunoglobuline G1-kappa, anti-[Homo sapiens EGFR
                                       (Récepteur du facteur de croissance épidermique,
                                       récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1,
                                       HER-1, ERBB)], anticorps monoclonal chimérique
                                       conjugué au maytansinoïde DM1;




                                                                                                                509
Recommended INN: List 76              WHO Drug Information, Vol. 30, No. 3, 2016


                           chaîne lourde gamma1 (1-448) [Mus musculus VH
                           (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01, Gm17,1 (CH1 (120-217), charnière
                           (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del
                           (448) (120-448)], (222-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01-
                           IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                           (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure;
                           conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde
                           DM1 via un linker succinimidyl-4-(N-maléimidométhyl)
                           cyclohexane-1-carboxylate (SMCC) formant une liaison
                           thioéther non réductible
                           Pour la partie emtansine, veuillez-vous référer au document ''INN for
                           pharmaceutical substances: Names for radicals, groups and others''*.


 laprituximab emtansina    inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR
                           (receptor del factor de crecimiento epidérmico, receptor
                           tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1,
                           ERBB)], anticuerpo monoclonal quimérico conjugado con
                           el maitansinoide DM1;
                           cadena pesada gamma1 (1-448) [Mus musculus VH
                           (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-
                           232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)
                           (120-448)], (222-214')-disulfuro con la cadena ligera kappa
                           (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01-
                           IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                           (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro;
                           conjugado, de 3 a 4 restos lisil por término medio, con el
                           maitansinoide DM1 mediante el conector succinimidil-
                           4-(N-maleimidometil) ciclohexano-1-carboxilato (SMCC)
                           formando una unión tioéter no reducible
                           La fracción emtensina se pueden encontrar en el documento "'INN for
                           pharmaceutical substances: Names for radicals, groups and others''*.




510
WHO Drug Information, Vol. 30, No. 3, 2016                          Recommended INN: List 76


 lenadogenum nolparvovecum #
 lenadogene nolparvovec                a non-replicating single stranded DNA recombinant adeno-
                                       associated virus (rAAV) serotype 2 containing human wt
                                       MT-ND4 cDNA that encodes NADH Dehydrogenase
                                       subunit 4, under the control of the cytomegalovirus
                                       immediate early (CMVie) promoter in an intron-containing
                                       expression cassette (beta globin intron, HBB2), flanked by
                                       the viral inverted terminal repeats from AAV2/2.

 lénadogène nolparvovec                vecteur viral adéno-associé de sérotype 2 recombinant
                                       (rAAV) non-répliquant, avec un ADN monocaténaire
                                       contenant le gène wt MT-ND4 codant pour la sous-unité 4
                                       de la NADH déshydrogénase humaine, sous le contrôle
                                       d’un cytomégalovirus immédiat précoce dans un intron
                                       contenant la cassette d’expression (intron bêta-globine,
                                       HBB2), flanqué de répétitions inverses dérivées du virus
                                       adéno-associé de sérotype 2

 lenadogén nolparvovec                 vector viral adeno-asociado de serotipo 2 recombinante
                                       (rAAV) no replicativo, con un ADN monocatenario que
                                       contiene el gen wt MT-ND4 que codifica para la subunidad
                                       4 de la NADH deshidrogenasa humano, bajo el control de
                                       un promotor inmediato temprano del citomegalovirus en un
                                       intron que contiene el cassette de expresión (intron beta-
                                       globin, HBB2), flanqueado de repeticiones inversas
                                       derivadas del virus adeno-asociado del serotipo 2


 leniolisibum
 leniolisib                            1-[(3S)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]-
                                       5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-
                                       4-yl}amino)pyrrolidin-1-yl]propan-1-one

 léniolisib                            1-[(3S)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyrimidin-3-yl]-
                                       5,6,7,8-tétrahydropyrido[4,3-d]pyrimidin-
                                       4-yl}amino)pyrrolidin-1-yl]propan-1-one

 leniolisib                            1-[(3S)-3-({6-[6-metoxi-5-(trifluorometil)pirimidin-3-il]-
                                       5,6,7,8-tetrahidropirido[4,3-d]pirimidin-4-il}amino)pirrolidin-
                                       1-il]propan-1-ona

                                       C21H25F3N6O2




 levoketoconazolum
 levoketoconazole                      1-{4-[4-({(2S,4R)-2-(2,4-dichlorophenyl)-2-[(1H-imidazol-
                                       1-yl)methyl]-1,3-dioxolan-4-yl}methoxy)phenyl]piperazin-
                                       1-yl}ethan-1-one




                                                                                                  511
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


 lévokétoconazole          1-{4-[4-({(2S,4R)-2-(2,4-dichlorophényl)-2-[(1H-imidazol-
                           1-yl)méthyl]-1,3-dioxolan-4-yl}méthoxy)phényl]pipérazin-
                           1-yl}éthan-1-one

 levoketoconazol           1-{4-[4-({(2S,4R)-2-(2,4-diclorofenil)-2-[(1H-imidazol-
                           1-il)metil]-1,3-dioxolan-4-il}metoxi)fenil]piperazin-1-il}etan-
                           1-ona

                           C26H28Cl2N4O4




 lorlatinibum
 lorlatinib                (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-
                           10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-
                           h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile

 lorlatinib                (10R)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-
                           10,15,16,17-tétrahydro-2H-4,8-méthénopyrazolo[4,3-
                           h][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile

 lorlatinib                (10R)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo-
                           10,15,16,17-tetrahidro-2H-4,8-metenopirazolo[4,3-
                           h][2,5,11]benzoxadiazaciclotetradecina-3-carbonitrilo

                           C21H19FN6O2




 lumateperonum
 lumateperone              1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-
                           2,3,6b,9,10,10a-hexahydro-
                           1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-
                           yl]butan-1-one

 lumatépérone              1-(4-fluorophényl)-4-[(6bR,10aS)-3-méthyl-
                           2,3,6b,9,10,10a-hexahydro-
                           1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-
                           butan-1-one

 lumateperona              1-(4-fluorofenil)-4-[(6bR,10aS)-3-metil-2,3,6b,9,10,10a-
                           hexahidro-1H-pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalin-
                           8(7H)-il]butan-1-ona




512
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76


                                       C24H28FN3O




 mesmulogenum ancovacivecum #
 mesmulogene ancovacivec               a non-replicating recombinant vaccinia virus, based on the
                                       Modified Vaccinia Virus Ankara (MVA) strain, carrying
                                       sequences coding for the expression of the human Mucine
                                       1 (MUC1) antigen and human Interleukin 2 (IL2), under the
                                       control of pH5R and p7.5 vaccinia promoters, respectively.

 mesmulogène ancovacivec               vecteur viral recombinant non-répliquant de la vaccine,
                                       dérivé du virus de la vaccine modifié Ankara, contenant les
                                       séquences d’ADN codant pour l’expression de l’antigène
                                       de la Mucine 1 et de l’interleukine 2 humaine, sous le
                                       contrôle des promoteurs pH5R et p7.5, respectivement

 mesmulogén ancovacivec                vector viral recombinante no replicativo de la vacuna,
                                       derivado de la cepa del virus de la vacuna modificada
                                       Ankara, que contiene las secuencias del ADN que codifica
                                       para la expresión del antígeno de la Mucina 1 (MUC1) y de
                                       la interleukina 2 humana (IL2), bajo el control de los
                                       promotores vaccinia pH5R y p7.5, respectivamente



 mipeginterferonum alfa-2b #
                                        2.1   6.Lys
 mipeginterferon alfa-2b               N ,N      -oligo(N-{2-[ω-methoxypoly(oxyethylene)-α-
                                       yl]acetyl}-N-[α-methylpoly(oxyethylene)-ω-yl]glycyl)human
                                       interferon alpha-2b, with an average number of 5
                                       substituted among 11 amino groups (one N-terminal and
                                                   6
                                       10 lysine N ), the protein part being produced in Pichia
                                       pastoris (Komagataella pastoris)
                                       The relative molecular mass of the polyethylene glycol part
                                       can be indicated after the INN, for example:
                                       mipeginterferon alfa-2b (40 kDa)
                                        2.1   6.Lys
 mipèginterféron alfa-2b               N ,N       -oligo(N-{2-[ω-méthoxypoly(oxyéthylène)-α-
                                       yl]acétyl}-N-[α-méthylpoly(oxyéthylène)-ω-
                                       yl]glycyl)interféron alpha-2b humain, une moyenne de 5
                                                                                           6
                                       azotes parmi les 11 (un N-terminal et 10 lysines N ) sont
                                       substitués, la partie protéique étant produite par Pichia
                                       pastoris (Komagataella pastoris)
                                       La masse molaire de la partie polyéthylène glycol peut être
                                       indiquée après la DCI, par exemple: mipèginterféron alfa-
                                       2b (40 kDa)




                                                                                              513
Recommended INN: List 76                  WHO Drug Information, Vol. 30, No. 3, 2016




                             2.1    6.Lys
 mipeginterferón alfa-2b   N ,N      -oligo(N-{2-[ω-metoxipoli(oxietileno)-α-il]acetil}-
                           N-[α-metilpoli(oxietileno)-ω-il]glicil)interferón alpha-2b
                           humano, con una media de 5 grupos amino sustituidos
                                                                         6
                           entre los 11 (un N-terminal y 10 lisinas N ), la parte
                           proteica es producida por Pichia pastoris (Komagataella
                           pastoris)
                           La masa molar de la parte polietilen glicol puede ser
                           indicada después de la DCI, por ejemplo: mipeginterferón
                           alfa-2b (40 kDa).

                            Sequence / Séquence / Secuencia
                            CDLPQTHSLG         SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA                                    50
                            ETIPVLHEMI         QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI                                    100
                            QGVGVTETPL         MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS                                    150
                            FSLSTNLQES         LRSKE                                                                          165
                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            1-98 29-138
                            Potential modified residues / Résidus potentiellement modifiés / Restos potencialmente modificados
                                         C                           R NH H                                           R
                                         1                        HS                                                    =
                                                                               CO2H H3CO                 O
                                                                                                                   O
                                                                                                                      O
                                         K                                    H                              n
                                                                                              H3C              N      C
                                31, 49, 70, 83, 112,                                                 O
                             121, 131, 133, 134, 164 R NH            H2N       CO2H                            n




 mirvetuximabum #
 mirvetuximab              immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1
                           (folate receptor 1, folate receptor alpha, FR-alpha, adult
                           folate-binding protein, FBP, ovarian tumor-associated
                           antigen MOv18)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1-
                           37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo sapiens
                           IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2
                           (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)],
                           (221-218')-disulfide with kappa light chain (1'-218') [Mus
                           musculus V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-
                           111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimer
                           (227-227'':230-230'')-bisdisulfide

 mirvétuximab              immunoglobuline G1-kappa, anti-[Homo sapiens FOLR1
                           (récepteur 1 du folate, récepteur alpha du folate, FR-alpha,
                           protéine de l’adulte liant le folate, FBP, antigène MOv18
                           associé à des tumeurs ovariennes)], anticorps monoclonal
                           chimérique;
                           chaîne lourde gamma1 (1-447) [Mus musculus VH
                           (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo
                           sapiens IGHG1*01, Gm17,1 (CH1 (119-216), charnière
                           (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del
                           (447)) (119-447)], (221-218')-disulfure avec la chaîne
                           légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-
                           9*01 -IGKJ2*01) [10.3.9] (1'-111') -Homo sapiens
                           IGKC*01, Km3 (112'-218')]; dimère (227-227'':230-230'')-
                           bisdisulfure




514
WHO Drug Information, Vol. 30, No. 3, 2016                                         Recommended INN: List 76




 mirvetuximab                          inmunoglobulina G1-kappa, anti-[Homo sapiens FOLR1
                                       (receptor 1 de folato, receptor alfa de folato, FR-alpha,
                                       proteína del adulto que liga el folato, FBP, antígeno Mov18
                                       asociado a tumores ováricos)], anticuerpo monoclonal
                                       quimérico;
                                       cadena pesada gamma1 (1-447) [Mus musculus VH
                                       (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-
                                       231), CH2 (232-341), CH3 (342-446), CHS K2>del (447))
                                       (119-447)], (221-218')-disulfuro con la cadena ligera kappa
                                       (1'-218') [Mus musculus V-KAPPA (IGKV3-9*01 -
                                       IGKJ2*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3
                                       (112'-218')]; dímero (227-227'':230-230'')-bisdisulfuro

                                        Heavy chain / Chaîne lourde / Cadena pesada
                                        QVQLVQSGAE VVKPGASVKI SCKASGYTFT                  GYFMNWVKQS       PGQSLEWIGR        50
                                        IHPYDGDTFY NQKFQGKATL TVDKSSNTAH                  MELLSLTSED       FAVYYCTRYD       100
                                        GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                        FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                        CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                        TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                        YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                        TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                        SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPG          447

                                        Light chain / Chaîne légère / Cadena ligera
                                        DIVLTQSPLS LAVSLGQPAI ISCKASQSVS                  FAGTSLMHWY       HQKPGQQPRL 50
                                        LIYRASNLEA GVPDRFSGSG SKTDFTLTIS                  PVEAEDAATY       YCQQSREYPY 100
                                        TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                        QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                        THQGLSSPVT KSFNRGEC                                                           218

                                        Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                        Intra-H (C23-C104)        22-96       145-201       262-322   368-426
                                                                  22''-96'' 145''-201'' 262''-322'' 368''-426''
                                        Intra-L (C23-C104)        23'-92'     138'-198'
                                                                  23'''-92''' 138'''-198'''
                                        Inter-H-L (h 5-CL 126) 221-218' 221''-218'''
                                        Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                        N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                        H CH2 N84.4:
                                        298, 298''
                                        Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                        complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 mizagliflozinum
 mizagliflozin                         3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-
                                       1H-pyrazol-4-yl]methyl}-3-methylphenoxy)propyl]amino}-
                                       2,2-dimethylpropanamide

 mizagliflozine                        3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-
                                       1H-pyrazol-4-yl]méthyl}-3-méthylphénoxy)propyl]amino}-
                                       2,2-diméthylpropanamide

 mizagliflozina                        3-{[3-(4-{[3-(β-D-glucopiranosiloxi)-5-(propan-2-il)-
                                       1H-pirazol-4-il]metil}-3-metilfenoxi)propil]amino}-
                                       2,2-dimetilpropanamida




                                                                                                                                  515
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016




                           C28H44N4O8




 nafithromycinum
                                 1
 nafithromycin             (3R,3 Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyl-
                           8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-
                           N'-{(1S)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]ethoxy}-
                           9-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
                           hexopyranosyl]oxy}tetradecahy-dro-2H-furo[2,3-
                           c]oxacyclotetradecine-3-carboximidamide
                                 1
 nafithromycine            (3R,3 Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-éthyl-
                           8-méthoxy-4,6,8,10,12,15a-hexaméthyl-2,5,11,13-tétraoxo-
                           N'-{(1S)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}-
                           9-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-
                           hexopyranosyl]oxy}tétradecahy-dro-2H-furo[2,3-
                           c]oxacyclotétradécine-3-carboximidamide
                                 1
 nafitromicina             (3R,3 Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-etil-
                           8-metoxi-4,6,8,10,12,15a-hexametil-2,5,11,13-tetraoxo-
                           N'-{(1S)-1-[5-(piridin-2-il)-1,3,4-tiadiazol-2-il]etoxi}-9-{[3,4,6-
                           tridesoxi-3-(dimetilamino)-β-D-xilo-
                           hexopiranosil]oxi}tetradecahidro-2H-furo[2,3-
                           c]oxaciclotetradecina-3-carboximidamida

                           C42H62N6O11S

                                     N

                                             S     H CH3              O
                                                                 H           CH3
                                         N              H3 C
                                             N                                H
                                                     O               NH        CH3
                                     H3C         H3CO
                                                                                O
                                                 O H3C          H2N
                                                                        H
                                                                      H
                                                        O                O         O
                                                            H         CH3 H
                                                                                 CH3
                               H3C N               OH       O                O
                                             CH3                     H CH3



 naratuximabum #
 naratuximab               immunoglobulin G1-kappa, anti-[Homo sapiens CD37
                           (tetraspanin-26, TSPAN26)], chimeric monoclonal
                           antibody;




516
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76




                                       gamma1 heavy chain (1-444) [Mus musculus VH (IGHV2-
                                       3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo sapiens
                                       IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2
                                       (229-338), CH3 (339-443), CHS K2>del (444) (116-444)],
                                       (218-214')-disulfide with kappa light chain (1'-214') [Mus
                                       musculus V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-
                                       107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                                       (224-224'':227-227'')-bisdisulfide

 naratuximab                           immunoglobuline G1-kappa, anti-[Homo sapiens CD37
                                       (tétraspanine-26, TSPAN26)], anticorps monoclonal
                                       chimérique;
                                       chaîne lourde gamma1 (1-444) [Mus musculus VH
                                       (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (116-213), charnière
                                       (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del
                                       (444) (116-444)], (218-214')-disulfure avec la chaîne légère
                                       kappa (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 -
                                       IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                       (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure

 naratuximab                           inmunoglobulina G1-kappa, anti-[Homo sapiens CD37
                                       (tetraspanina-26, TSPAN26)], anticuerpo monoconal
                                       quimérico;
                                       cadena pesada gamma1 (1-444) [Mus musculus VH
                                       (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-
                                       228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)
                                       (116-444)], (218-214')-disulfuro con cadena ligera kappa
                                       (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 -
                                       IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                       (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro




                                                                                               517
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016




 naratuximabum emtansinum #
 naratuximab emtansine        immunoglobulin G1-kappa, anti-[Homo sapiensCD37
                              (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody
                              conjugated to maytansinoid DM1;
                              gamma1 heavy chain (1-444) [Mus musculus VH (IGHV2-
                              3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo sapiens
                              IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2
                              (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)],
                              (218-214')-disulfide with kappa light chain (1'-214') [Mus
                              musculus V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-
                              107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer
                              (224-224'':227-227'')-bisdisulfide; conjugated, on an
                              average of 3 to 4 lysyl, to maytansinoid DM1 via a
                              succinimidyl-4-(N-maleimidomethyl) cyclohexane-
                              1-carboxylate (SMCC) linker forming a nonreducible
                              thioether bond
                              For the emtansine part, please refer to the document ''INN for pharmaceutical
                              substances: Names for radicals, groups and others''*.


 naratuximab emtansine        immunoglobuline G1-kappa, anti-[Homo sapiensCD37
                              (tétraspanine-26, TSPAN26)], anticorps monoclonal
                              chimérique conjugué au maytansinoïde DM1;
                              chaîne lourde gamma1 (1-444) [Mus musculus VH
                              (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo
                              sapiens IGHG1*01, Gm17,1 (CH1 (116-213), charnière
                              (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del
                              (444)) (116-444)], (218-214')-disulfure avec la chaîne
                              légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV12-
                              46*01 - IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                              IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-
                              bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au
                              maytansinoïde DM1 via un linker succinimidyl-
                              4-(N-maléimidométhyl) cyclohexane-1-carboxylate (SMCC)
                              formant une liaison thioéther non réductible
                              Pour la partie emtansine, veuillez-vous référer au document ''INN for
                              pharmaceutical substances: Names for radicals, groups and others''*.


 naratuximab emtansina        inmunoglobulina G1-kappa, anti-[Homo sapiensCD37
                              (tetraspanina-26, TSPAN26)], anticuerpo monoclonal
                              quimérico conjugado con maitansinoide DM1;
                              cadena pesada gamma1 (1-444) [Mus musculus VH
                              (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo
                              sapiens IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-
                              228), CH2 (229-338), CH3 (339-443), CHS K2>del (444))
                              (116-444)], (218-214')-disulfuro con cadena ligera kappa
                              (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 -
                              IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                              (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro;
                              conjugado, en una media de 3 a 4 restos lisil, con
                              maitansinoide DM1 mediante un conector succinimidil
                              -4-(N-maleimidometil) ciclohexano-1-carboxilato (SMCC)
                              formando una unión tioéter no reducible
                              La fracción emtensina se pueden encontrar en el documento "'INN for
                              pharmaceutical substances: Names for radicals, groups and others''*.




518
WHO Drug Information, Vol. 30, No. 3, 2016                      Recommended INN: List 76




 navamepentum
 navamepent                            propan-2-yl (5S,8E,10E,12R)-5,12-dihydroxypentadeca-
                                       8,10-diene-6,14-diynoate

 navamépent                            (5S,8E,10E,12R)-5,12-dihydroxypentadéca-8,10-diène-
                                       6,14-diynoate de propan-2-yle

 navamepent                            (5S,8E,10E,12R)-5,12-dihidroxipentadeca-8,10-dieno-
                                       6,14-diinoato de propan-2-ilo

                                       C18H24O4




 navicixizumabum #
 navicixizumab                         immunoglobulin G2-kappa, anti-[Homo sapiens DLL4
                                       (delta-like 4)] and anti-[Homo sapiens VEGFA (vascular
                                       endothelial growth factor A,VEGF-A, VEGF)], humanized
                                       and chimeric monoclonal antibody, bispecific;




                                                                                             519
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




                           gamma2 heavy chain, humanized anti-DLL4 (1-445)
                           [humanized VH (Homo sapiens IGHV1-18*01 (84.70%) -
                           (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens
                           IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-
                           338), CH3 (339-443) K26>E (368), K88>E (407), CHS
                           (444-445)) (120-445)],(133-218')-disulfide with kappa light
                           chain, chimeric (1’-218’) [chimeric V-KAPPA (Mus
                           musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9]
                           (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')];
                           gamma2 heavy chain, humanized anti-VEGFA (1-447)
                           [humanized VH (Homo sapiens IGHV1-46*01 (83.30%) -
                           (IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens
                           IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232-
                           340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS
                           (446-447)) (122-447)], (135'-218''')-disulfide with kappa
                           light chain, chimeric (1'''-218''') [chimeric V-KAPPA (Mus
                           musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9]
                           (1'''-111''') -Homo sapiens IGKC*01, Km3 (112'''-218''')];
                           dimer (221-223":222-224":225-227":228-230")-
                           tetrakisdisulfide


 navicixizumab             immunoglobuline G2-kappa, anti-[Homo sapiens DLL4
                           (delta-like 4)] et anti-[Homo sapiens VEGFA (facteur de
                           croissance A de l’endothélium vasculaire, VEGF-A,
                           VEGF)], anticorps monoclonal humanisé et chimérique,
                           bispécifique;
                           chaîne lourde gamma2, humanisée anti-DLL4 (1-445) [VH
                           humanisé (Homo sapiens IGHV1-18*01 (84.70%) -(IGHD)-
                           IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG2*01
                           (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3
                           (339-443) K26>E (368), K88>E (407), CHS (444-445))
                           (120-445)], (133-218')-disulfure avec la chaîne légère
                           kappa, chimérique (1’-218’) [V-KAPPA chimérique (Mus
                           musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9]
                           (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')];
                           chaîne lourde gamma2, humanisée anti-VEGFA (1-447)
                           [VH humanisé (Homo sapiens IGHV1-46*01 (83.30%) -
                           (IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens
                           IGHG2*01 (CH1 (122-219), charnière (220-231), CH2
                           (232-340), CH3 (341-445) E13>K (357), D84.2>K (399),
                           CHS (446-447)) (122-447)], (135'-218''')-disulfure avec la
                           chaîne légère kappa, chimérique (1'''-218''') [V-KAPPA
                           chimérique (Mus musculus IGKV3-2*01 -Homo sapiens
                           IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens IGKC*01,
                           Km3 (112'''-218''')]; dimère (221-223":222-224":225-
                           227":228-230")-tétrakisdisulfure


 navicixizumab             inmunoglobulina G2-kappa, anti-[Homo sapiens DLL4
                           (delta-like 4)] y anti-[Homo sapiens VEGFA (factor de
                           crecimiento A del endotelio vascular,VEGF-A, VEGF)],
                           anticuerpo humanizado y quimérico, biespecífico;




520
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76


                                       cadena pesada gamma2, humanizada anti-DLL4 (1-445)
                                       [VH humanizado (Homo sapiens IGHV1-18*01 (84.70%) -
                                       (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens
                                       IGHG2*01 (CH1 (120-217), bisagra (218-229), CH2 (230-
                                       338), CH3 (339-443) K26>E (368), K88>E (407), CHS
                                       (444-445)) (120-445)], (133-218')-disulfuro con la cadena
                                       ligera kappa, quimérica (1’-218’) [V-KAPPA quimérico
                                       (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01)
                                       [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-
                                       218')]; cadena pesada gamma2, humanizada anti-VEGFA
                                       (1-447) [VH humanizado (Homo sapiens IGHV1-46*01
                                       (83.30%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo
                                       sapiens IGHG2*01 (CH1(122-219), bisagra (220-231),
                                       CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K
                                       (399), CHS (446-447)) (122-447)], (135'-218''')-disulfuro
                                       con la cadena ligera kappa, quimérica (1'''-218''') [V-
                                       KAPPA quimérico (Mus musculus IGKV3-2*01 -Homo
                                       sapiens IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens
                                       IGKC*01, Km3 (112'''-218''')]; dímero (221-223":222-
                                       224":225-227":228-230")-tetrakisdisulfuro




 nazartinibum
 nazartinib                            N-(7-chloro-1-{(3R)-1-[(2E)-4-(dimethylamino)but-
                                       2-enoyl]azepan-3-yl}-1H-benzimidazol-2-yl)-
                                       2-methylpyridine-4-carboxamide

 nazartinib                            N-(7-chloro-1-{(3R)-1-[(2E)-4-(diméthylamino)but-
                                       2-énoyl]azépan-3-yl}-1H-benzimidazol-2-yl)-
                                       2-méthylpyridine-4-carboxamide




                                                                                             521
Recommended INN: List 76                WHO Drug Information, Vol. 30, No. 3, 2016



 nazartinib                N-(7-cloro-1-{(3R)-1-[(2E)-4-(dimetilamino)but-
                           2-enoil]azepan-3-il}-1H-benzimidazol-2-il)-2-metilpiridina-
                           4-carboxamida

                           C26H31ClN6O2



                              Cl                N                     CH3
                                    H                             N
                                        N
                                                     O            CH3
                                            NH
                                        N                 N
                                            O
                                                          CH3


 nicodicosapentum
 nicodicosapent            N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
                           pentaenamido]ethyl}pyridine-3-carboxamide

 nicodicosapent            N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
                           pentaénamido]éthyl}pyridine-3-carboxamide

 nicodicosapent            N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
                           pentaenamido]etil}piridina-3-carboxamida

                           C28H39N3O2




 nolasibanum
 nolasiban                 [(2S,4Z)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-
                           1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone

 nolasiban                 [(2S,4Z)-2-(hydroxyméthyl)-4-(méthoxyimino)pyrrolidin-
                           1-yl](2'-méthyl[1,1'-biphényl]-4-yl)méthanone

 nolasibán                 (2S,4Z)-2-(hidroximetil)-4-(metoxiimino)pirrolidin-1-il](2'-
                           metil[1,1'-bifenil]-4-il)metanona

                           C20H22N2O3

                                                     OH

                                                H
                                                              N
                              CH3                    N
                                                                  O CH3
                                                 O

 oliceridinum
 oliceridine               N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-(pyridin-
                           2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine




522
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




 olicéridine                           N-[(3-méthoxythiophén-2-yl)méthyl]-2-[(9R)-9-(pyridin-
                                       2-yl)-6-oxaspiro[4.5]décan-9-yl]éthan-1-amine

 oliceridina                           N-[(3-metoxitiofen-2-il)metil]-2-[(9R)-9-(piridin-2-il)-
                                       6-oxaspiro[4.5]decan-9-il]etan-1-amina

                                       C22H30N2O2S




 olmutinibum
 olmutinib                             N-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-
                                       d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide

 olmutinib                             N-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]thiéno[3,2-
                                       d]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

 olmutinib                             N-[3-({2-[4-(4-metilpiperazina-1-il)anilino]tieno[3,2-
                                       d]pirimidin-4-il}oxi)fenil]prop-2-enamida

                                       C26H26N6O2S




 olumacostatum glasaretilum
 olumacostat glasaretil                2-[(2-ethoxy-2-oxoethyl)(methyl)amino]-2-oxoethyl 5-
                                       (tetradecyloxy)furan-2-carboxylate

 olumacostat glasarétil                5-(tétradécyloxy)furane-2-carboxylate de 2-[(2-éthoxy-2-
                                       oxoéthyl)(méthyl)amino]-2-oxoéthyle

 olumacostat glasaretilo               5-(tetradeciloxi)furan-2-carboxilato de 2-[(2-etoxi-2-
                                       oxoetil)(metil)amino]-2-oxoetilo

                                       C26H43NO7




                                                                                                  523
Recommended INN: List 76             WHO Drug Information, Vol. 30, No. 3, 2016




 omidenepagum
 omidenepag                ({6-[(N-{[4-(1H-pyrazol-1-yl)phenyl]methyl}pyridine-
                           3-sulfonamido)methyl]pyridin-2-yl}amino)acetic acid

 omidénépag                acide ({6-[(N-{[4-(1H-pyrazol-1-yl)phényl]méthyl}pyridine-
                           3-sulfonamido)méthyl]pyridin-2-yl}amino)acétique

 omidenepag                ácido ({6-[(N-{[4-(1H-pirazol-1-il)fenil]metil}piridina-
                           3-sulfonamido)metil]piridin-2-il}amino)acético

                           C23H22N6O4S

                                          H
                                          N    CO2H

                                      N


                                      N
                                      S O                 N
                            N                         N
                                       O




 oteseconazolum
 oteseconazole             (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3,4-
                           tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-
                           2-yl}propan-2-ol

 otéséconazole             (2R)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1H-1,2,3,4-
                           tétrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin-
                           2-yl}propan-2-ol

 oteseconazol              (2R)-2-(2,4-difluorofenil)-1,1-difluoro-3-(1H-1,2,3,4-tetrazol-
                           1-il)-1-{5-[4-(2,2,2-trifluoroetoxi)fenil]piridin-2-il}propan-2-ol

                           C23H16F7N5O2




 pibrentasvirum
 pibrentasvir              dimethyl N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4-
                           fluorophenyl)piperidin-1-yl]phenyl}pyrrolidine-
                           2,5-diyl]bis{(6-fluoro-1H-benzimidazole-5,2-diyl)[(2S)-
                           pyrrolidine-2,1-diyl][(2S,3R)-3-methoxy-1-oxobutane-
                           1,2-diyl]})dicarbamate




524
WHO Drug Information, Vol. 30, No. 3, 2016                          Recommended INN: List 76




 pibrentasvir                          N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4-
                                       fluorophényl)pipéridin-1-yl]phényl}pyrrolidine-
                                       2,5-diyl]bis{(6-fluoro-1H-benzimidazole-5,2-diyl)[(2S)-
                                       pyrrolidine-2,1-diyl][(2S,3R)-3-méthoxy-1-oxobutane-
                                       1,2-diyl]})dicarbamate de diméthyle

 pibrentasvir                          N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-
                                       1-il]fenil}pirrolidina-2,5-diil]bis{(6-fluoro-1H-benzimidazol-
                                       5,2-diil)[(2S)-pirrolidina-2,1-diil][(2S,3R)-3-metoxi-
                                       1-oxobutano-1,2-diil]})dicarbamato de dimetil

                                       C57H65F6N10O8




 prexasertibum
 prexasertib                           5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-
                                       3-yl}amino)pyrazine-2-carbonitrile

 prexasertib                           5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1H-pyrazol-
                                       3-yl}amino)pyrazine-2-carbonitrile

 prexasertib                           5-({5-[2-(3-aminopropoxi)-6-metoxifenil]-1H-pirazol-
                                       3-il}amino)pirazina-2-carbonitrilo

                                       C18H19N7O2




                                                                                                  525
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016


 prexigebersenum
 prexigebersen             2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-
                           2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
                           2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
                           2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-
                           thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
                           2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
                           thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine

 prexigébersen             2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-
                           2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
                           (3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
                           2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
                           2'-déoxyguanylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-
                           thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
                           2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
                           thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidine

 prexigebersén             2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiadenilil-
                           (3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-
                           2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
                           2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
                           2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil-
                           (3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-
                           timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidina

                           C177H224N63O110P17

                           (3'-5')d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C)
 prezalumabum #
 prezalumab                immunoglobulin G2-kappa, anti-[Homo sapiens ICOSL
                           (inducible T-cell co-stimulatory ligand, B7 homologue 2,
                           B7H2, B7-H2, B7-related protein 1, B7RP1, B7RP-1,
                           CD275)], Homo sapiens monoclonal antibody;
                           gamma2 heavy chain (1-447) [Homo sapiens VH (IGHV3-
                           7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -
                           IGHG2*01, G2m.. (CH1 (122-219), hinge (220-231), CH2
                           (232-340), CH3 (341-445), CHS (446-447)) (122-447)],
                           (135-214')-disulfide with kappa light chain (1'-214') [Homo
                           sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01)
                           [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223-
                           223'':224-224'':227-227'':230-230'')-tetrakisdisulfide

 prézalumab                immunoglobuline G2-kappa, anti-[Homo sapiens ICOSL
                           (ligand inductible co-stimulateur des cellules T, homologue
                           2 du B7, B7H2, B7-H2, protéine 1 apparentée au B7,
                           B7RP1, B7RP-1, CD275)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma2 (1-447) [Homo sapiens VH
                           (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-
                           121) -IGHG2*01, G2m.. (CH1 (122-219), charnière (220-
                           231), CH2 (232-340), CH3 (341-445), CHS (446-447))
                           (122-447)], (135-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV2D-16*01
                           (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                           214')]; dimère (223-223'':224-224'':227-227'':230-230'')-
                           tétrakisdisulfure




526
WHO Drug Information, Vol. 30, No. 3, 2016                        Recommended INN: List 76




 prezalumab                            inmunoglobulina G2-kappa, anti-[Homo sapiens ICOSL
                                       (ligando inducible co-estimulador de las células T, B7
                                       homólogo 2, B7H2, B7-H2, proteína 1 relacionada con la
                                       B7, B7RP1, B7RP-1, CD275)], Homo sapiens anticuerpo
                                       monoclonal;
                                       cadena pesada gamma2 (1-447) [Homo sapiens VH
                                       (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-
                                       121) -IGHG2*01, G2m.. (CH1 (122-219), bisagra (220-
                                       231), CH2 (232-340), CH3 (341-445), CHS (446-447))
                                       (122-447)], (135-214')-disulfuro con la cadena ligera kappa
                                       (1'-214') [Homo sapiens V-KAPPA (IGKV2D-16*01
                                       (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                                       214')]; dímero (223-223'':224-224'':227-227'':230-230'')-
                                       tetrakisdisulfuro




 redaporfinum
 redaporfin                            3,3',3'',3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-
                                       tetrayl)tetrakis(2,4-difluoro-N-methylbenzenesulfonamide)

 rédaporfine                           3,3',3'',3'''-(7,8,17,18-tétrahydroporphyrin-5,10,15,20-
                                       tétrayl)tétrakis(2,4-difluoro-N-méthylbenzènesulfonamide)

 redaporfina                           3,3',3'',3'''-(7,8,17,18-tetrahidroporfirin-5,10,15,20-
                                       tetrail)tetrakis(2,4-difluoro-N-metilbencenosulfonamida)




                                                                                                  527
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016




                           C48H38F8N8O8S4

                                                             O O
                                                              S   CH3
                                                                N
                                                                H
                            H3C                    F             F
                                    NH
                            O
                                S         F                          F
                            O                          NH   N


                                                       N    HN                    O
                                          F                          F        S
                                                                                  O
                                                                         HN
                                                   F             F            CH3
                                               H
                                               N
                                         H3C    S
                                               O O




 refanezumabum #
 refanezumab               immunoglobulin G1-kappa, anti-[Homo sapiens MAG
                           (myelin associated glycoprotein, sialic acid binding Ig-like
                           lectin 4A, SIGLEC4A, SIGLEC-4A)], humanized
                           monoclonal antibody;
                           gamma1 heavy chain (1-456) [humanized VH (Homo
                           sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01)
                           [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (127-224), hinge (225-239), CH2 L1.2>A (244), G1>A
                           (246) (240-349), CH3 (350-454), CHS (455-456)) (127-
                           456)], (229-219')-disulfide with kappa light chain (1’-219’)
                           [humanized V-KAPPA (Homo sapiens IGKV4-1*01
                           (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens
                           IGKC*01, Km3 (113'-219')]; dimer (235-235":238-238")-
                           bisdisulfide

 réfanézumab               immunoglobuline G1-kappa, anti-[Homo sapiens MAG
                           (glycoprotéine associée à la myéline, lectine 4A Ig-like liant
                           l’acide sialique, SIGLEC4A, SIGLEC-4A)], anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma1 (1-456) [humanisé VH (Homo
                           sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01)
                           [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                           (127-224), charnière (225-239), CH2 L1.2>A (244), G1>A
                           (246) (240-349), CH3 (350-454), CHS (455-456)) (127-
                           456)], (229-219')- disulfure avec la chaîne légère kappa
                           (1’-219’) [V-KAPPA humanisé (Homo sapiens IGKV4-1*01
                           (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens
                           IGKC*01, Km3 (113'-219')]; dimère (235-235":238-238")-
                           bisdisulfure




528
WHO Drug Information, Vol. 30, No. 3, 2016                                         Recommended INN: List 76




 refanezumab                           inmunoglobulina G1-kappa, anti-[Homo sapiens MAG
                                       (glicoproteína asociada a la mielina, lectina de tipo
                                       inmunoglobulina 4A que se une al ácido siálico,
                                       SIGLEC4A, SIGLEC-4A)], anticuerpo monoclonal
                                       humanizado;
                                       cadena pesada gamma1 (1-456) [VH humanizado (Homo
                                       sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01)
                                       [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1
                                       (127-224), bisagra (225-239), CH2 L1.2>A (244), G1>A
                                       (246) (240-349), CH3 (350-454), CHS (455-456)) (127-
                                       456)], (229-219')-disulfuro con la cadena ligera kappa (1’-
                                       219’) [V-KAPPA humanizado (Homo sapiens IGKV4-1*01
                                       (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens
                                       IGKC*01, Km3 (113'-219')]; dímero (235-235":238-238")-
                                       bisdisulfuro

                                        Heavy chain / Chaîne lourde / Cadena pesada
                                        QVQLVQSGSE LKKPGASVKV SCKASGYTFT                  NYGMNWVRQA       PGQGLEWMGW        50
                                        INTYTGEPTY ADDFTGRFVF SLDTSVSTAY                  LQISSLKAED       TAVYYCARNP       100
                                        INYYGINYEG YVMDYWGQGT LVTVSSASTK                  GPSVFPLAPS       SKSTSGGTAA       150
                                        LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP                  AVLQSSGLYS       LSSVVTVPSS       200
                                        SLGTQTYICN VNHKPSNTKV DKKVEPKSCD                  KTHTCPPCPA       PELAGAPSVF       250
                                        LFPPKPKDTL MISRTPEVTC VVVDVSHEDP                  EVKFNWYVDG       VEVHNAKTKP       300
                                        REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC                  KVSNKALPAP       IEKTISKAKG       350
                                        QPREPQVYTL PPSRDELTKN QVSLTCLVKG                  FYPSDIAVEW       ESNGQPENNY       400
                                        KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN                  VFSCSVMHEA       LHNHYTQKSL       450
                                        SLSPGK                                                                              456

                                        Light chain / Chaîne légère / Cadena ligera
                                        DIVMTQSPDS LAVSLGERAT INCKSSHSVL                  YSSNQKNYLA       WYQQKPGQPP 50
                                        KLLIYWASTR ESGVPDRFSG SGSGTDFTLT                  ISSLQAEDVA       VYYCHQYLSS 100
                                        LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                        VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                        VTHQGLSSPV TKSFNRGEC                                                          219

                                        Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                        Intra-H (C23-C104)        22-96       153-209       270-330   376-434
                                                                  22''-96'' 153''-209'' 270''-330'' 376''-434''
                                        Intra-L (C23-C104)        23'-94'     139'-199'
                                                                  23'''-94''' 139'''-199'''
                                        Inter-H-L (h 5-CL 126) 229-219' 229''-219'''
                                        Inter-H-H (h 11, h 14) 235-235'' 238-238''

                                        N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                        H CH2 N84.4:
                                        306, 306''
                                        Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                                        complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 revefenacinum
 revefenacin                           1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-
                                       N-methylbenzamido}ethyl)piperidin-4-yl N-([1,1'-biphenyl]-
                                       2-yl)carbamate

 révéfénacine                          N-([1,1'-biphényl]-2-yl)carbamate de
                                       1-(2-{4-[(4-carbamoylpipéridin-1-yl)méthyl]-
                                       N-méthylbenzamido}éthyl)pipéridin-4-yle

 revefenacina                          N-([1,1'-bifenil]-2-il)carbamato de
                                       1-(2-{4-[(4-carbamoilpiperidin-1-il)metil]-
                                       N-metilbenzamida}etil)piperidin-4-il




                                                                                                                                529
Recommended INN: List 76           WHO Drug Information, Vol. 30, No. 3, 2016




                           C35H43N5O4



                                                            O                  O
                                   H
                                   N       O      H3C
                                                        N                          NH2
                                       O         N                     N




 rivabazumabum #
 rivabazumab               immunoglobulin Fab' G1-kappa, anti-[Pseudomonas
                           aeruginosa type III secretion system (TTSS) PcrV protein],
                           humanized monoclonal antibody;
                           gamma1 heavy chain fragment VH-(CH1-hinge) (1-238)
                           [humanized VH (Homo sapiens IGHV3-30*06 (92.90%) -
                           (IGHD) -IGHJ6*01) [8.8.17] (1-124) -Homo sapiens
                           IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237),
                           CH2 (238)) (125-238)], noncovalently associated with
                           kappa light chain (1’-214’) [humanized V-KAPPA (Homo
                           sapiens IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -
                           Homo sapiens IGKC*01 C126>S (214') (108'-214')]


 rivabazumab               immunoglobuline Fab' G1-kappa, anti-[protéine PcrV du
                           système de sécrétion type III (TTSS) de Pseudomonas
                           aeruginosa], anticorps monoclonal humanisé;
                           fragment VH-(CH1-charnière) de la chaîne lourde gamma1
                           (1-238) [VH humanisé (Homo sapiens IGHV3-30*06
                           (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -Homo
                           sapiens IGHG1*01 (CH1 (125-222), charnière C5>S (227)
                           (223-237), CH2 (238)) (125-238)], associé de manière non
                           covalente avec la chaîne légère kappa (1’-214’) [V-KAPPA
                           humanisé (Homo sapiens IGKV1-5*01 (84.60%) -
                           IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           C126>S (214') (108'-214')]


 rivabazumab               inmunoglobulina Fab' G1-kappa, anti-[proteína PcrV del
                           sistema de secreción tipo III (TTSS) de Pseudomonas
                           aeruginosa], anticuerpo monoclonal humanizado;
                           fragmento VH-(CH1-bisagra) de la cadena pesada
                           gamma1 (1-238) [VH humanizado (Homo sapiens IGHV3-
                           30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -
                           Homo sapiens IGHG1*01 (CH1 (125-222), bisagra C5>S
                           (227) (223-237), CH2 (238)) (125-238)], asociado de modo
                           nocovalente con la cadena ligera kappa (1’-214’) [V-
                           KAPPA humanizado (Homo sapiens IGKV1-5*01 (84.60%)
                           -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           C126>S (214') (108'-214')]




530
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




 ruclosporinum
 ruclosporin                           8-[(2R)-N-methyl-2-[2-(4-
                                       morpholinyl)ethoxy]glycine]cyclosporin A:
                                        cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-
                                       L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-3-hydroxy-
                                       N,4-dimethyl-L-2-aminooct-6-enoyl-L-2-aminobutanoyl-
                                       (2R)-N-methyl-2-[2-(morpholin-4-yl)ethoxy]glycyl-N-methyl-
                                       L-leucyl-L-valyl-N-methyl-L-leucyl]

 ruclosporine                          8-[(2R)-N-méthyl-2-[2-(4-
                                       morpholinyl)éthoxy]glycine]cyclosporine A:
                                        cyclo[L-alanyl-D-alanyl-N-méthyl-L-leucyl-N-méthyl-
                                       L-leucyl-N-méthyl-L-valyl-(3R,4R,6E)-3-hydroxy-
                                       N,4-diméthyl-L-2-aminooct-6-énoyl-L-2-aminobutanoyl-
                                       (2R)-N-méthyl-2-[2-(morpholin-4-yl)éthoxy]glycyl-N-méthyl-
                                       L-leucyl-L-valyl-N-méthyl-L-leucyl]

 ruclosporina                          8-[(2R)-N-metil-2-[2-(4-morfolinil)etoxi]glicina]ciclosporina
                                       A:
                                       ciclo[L-alanil-D-alanil-N-metil-L-leucil-N-metil-L-leucil-
                                       N-metil-L-valil-(3R,4R,6E)-3-hidroxi-N,4-dimetil-
                                       L-2-aminooct-6-enoil-L-2-aminobutanoil-(2R)-N-metil-
                                       2-[2-(morfolin-4-il)etoxi]glicil-N-metil-L-leucil-L-valil-N-metil-
                                       L-leucil]

                                       C68H122N12O14




                                                                                                     531
Recommended INN: List 76               WHO Drug Information, Vol. 30, No. 3, 2016




 ruzasvirum
 ruzasvir                    dimethyl N,N'-([(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-
                             1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-
                             3,10-diyl]bis{(1H-imidazole-4,2-diyl)[(2S)-pyrrolidine-
                             2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

 ruzasvir                    N,N'-([(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-
                             6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{(1H-
                             imidazole-4,2-diyl)[(2S)-pyrrolidine-2,1-diyl][(2S)-3-méthyl-
                             1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

 ruzasvir                    N,N'-([(6S)-6-(2-ciclopropil-1,3-tiazol-5-il)-1-fluoro-
                             6H-indolo[1,2-c][1,3]benzoxazina-3,10-diil]bis{(1H-
                             imidazol-4,2-diil)[(2S)-pirrolidina-2,1-diil][(2S)-3-metil-
                             1-oxobutano-1,2-diil]})dicarbamato de dimetilo

                             C49H55FN10O7S




 satoreotidum trizoxetanum
                              2   7
 satoreotide trizoxetan      S ,S -cyclo[N-{(4RS)-4-[4,7-bis(carboxymethyl)-
                             1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro-
                             L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-
                             4-carb-oxamido]-L-phenylalanyl-4-(carbamoylamino)-
                             D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-
                             D-tyrosinamide]

                              2   7
 satoréotide trizoxétan      S ,S -cyclo[N-{(4RS)-4-[4,7-bis(carboxyméthyl)-
                             1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro-
                             L-phénylalanyl-D-cystéinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-
                             4-carb-oxamido]-L-phénylalanyl-4-(carbamoylamino)-
                             D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl-
                             D-tyrosinamide]

                              2   7
 satoreotida trizoxetán      S ,S -ciclo[N-{(4RS)-4-[4,7-bis(carboximetil)-
                             1,4,7-triazonan-1-il]-4-carboxibutanoil}-4-cloro-L-fenilalanil-
                             D-cisteinil-4-[(4S)-2,6-dioxo-1,3-diazinano-4-carboxamido]-
                             L-fenilalanyl-4-(carbamoilamino)-D-fenilalanil-L-lisil-
                             L-treonil-L-cisteinil-D-tirosinamida]




532
WHO Drug Information, Vol. 30, No. 3, 2016                          Recommended INN: List 76


                                       C73H95ClN18O21S2




 seviteronelum
 seviteronel                           (1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-
                                       1-(1H-1,2,3-triazole-4-yl)propan-1-ol

 sevitéronel                           (1S)-1-[6,7-bis(difluorométhoxy)naphtalén-2-yl]-2-méthyl-
                                       1-(1H-1,2,3-triazole-4-yl)propan-1-ol

 seviteronel                           (1S)-1-[6,7-bis(difluorometoxi)naftalen-2-il]-2-metil-
                                       1-(1H-1,2,3-triazol-4-il)propan-1-ol

                                       C18H17F4N3O3




 sitravatinibum
 sitravatinib                          N-(3-fluoro-4-{[2-(5-{[(2-
                                       methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-
                                       b]pyridin-7-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-
                                       1,1-dicarboxamide

 sitravatinib                          N-(3-fluoro-4-{[2-(5-{[(2-
                                       méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2-
                                       b]pyridin-7-yl]oxy}phényl)-N'-(4-fluorophényl)cyclopropane-
                                       1,1-dicarboxamide

 sitravatinib                          N-(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin-
                                       2-il)tieno[3,2-b]piridin-7-il]oxi}fenil)-
                                       N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

                                       C33H29F2N5O4S




                                                                                                   533
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 talinexomerum
 talinexomer               poly[(prop-2-enoic acid)-co-{2-ethyl-2-[(prop-
                           2-enoyloxy)methyl]propane-1,3-diyl di(prop-2-enoate)}]

 talinexomère              poly[(acide prop-2-énoïque)-co-{di(prop-2-énoate) de
                           2-éthyl-2-[(prop-2-énoyloxy)méthyl]propane-1,3-diyle}]

 talinexómero              poli[(ácido prop-2-enoico)-co-{di(prop-2-enoato de 2-etil-
                           2-[(prop-2-enoiloxi)metil]propano-1,3-diilo}]

                           [[C15H20O6]x . [C3H4O2]y]n y/x ≈ 1000




 tamtuvetmabum #
 tamtuvetmab               immunoglobulin G2_V-kappa-C-lambda, anti-[Homo
                           sapiens CD52], caninized monoclonal antibody;
                           gamma2 heavy chain chimeric (1-456) [chimeric VH
                           (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis
                           lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis
                           lupus familiaris IGHG2*02 (CH1 (122-219), hinge (220-
                           237), CH2 (238-347), CH3 (348-454), CHS (455-
                           456))(122-456)], (136-212')-disulfide with V-kappa-
                           C-lambda light chain chimeric (1'-213') [Rattus norvegicus
                           V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) -
                           IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris
                           IGLC1S1*01 V45.3>I (156) (108'-213')]; dimer (233-
                           233'':236-236'')-bisdisulfide

 tamtuvetmab               immunoglobuline G2_V-kappa-C-lambda, anti-[Homo
                           sapiens CD52], anticorps monoclonal caninisé;
                           chaîne lourde gamma2 chimérique (1-456) [VH chimérique
                           (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis
                           lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis
                           lupus familiaris IGHG2*02 (CH1 (122-219), charnière (220-
                           237), CH2 (238-347), CH3 (348-454), CHS (455-456))
                           (122-456)], (136-212')-disulfure avec la chaîne légère
                           V-kappa-C-lambda chimérique (1'-213') [Rattus norvegicus
                           V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) -
                           IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris
                           IGLC1S1*01 V45.3>I (156) (108'-213')]; dimère (233-
                           233'':236-236'')-bisdisulfure

 tamtuvetmab               inmunoglobulina G2_V-kappa-C-lambda, anti-[Homo
                           sapiens CD52], anticuerpo monoclonal caninizado;




534
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76


                                       cadena pesada gamma2 quimérica (1-456) [VH quimérico
                                       (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis
                                       lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis
                                       lupus familiaris IGHG2*02 (CH1 (122-219), bisagra (220-
                                       237), CH2 (238-347), CH3 (348-454), CHS (455-
                                       456))(122-456)], (136-212')-disulfuro con la cadena ligera
                                       V-kappa-C-lambda quimérica (1'-213') [Rattus norvegicus
                                       V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) -
                                       IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris
                                       IGLC1S1*01 V45.3>I (156) (108'-213')]; dímero (233-
                                       233'':236-236'')-bisdisulfuro




 tarloxotinibi bromidum
 tarloxotinib bromide                  (2E)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-
                                       6-yl]amino}-N,N-dimethyl-N-[(1-methyl-4-nitro-1H-imidazol-
                                       5-yl)methyl]-4-oxobut-2-en-1-aminium bromide

 bromure de tarloxotinib               bromure de (2E)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-
                                       d]pyrimidin-6-yl]amino}-N,N-diméthyl-N-[(1-méthyl-4-nitro-
                                       1H-imidazol-5-yl)méthyl]-4-oxobut-2-én-1-aminium

 bromuro de tarloxotinib               bromuro de (2E)-4-{[4-(3-bromo-4-cloroanilino)pirido[3,4-
                                       d]pirimidin-6-il]amino}-N,N-dimetil-N-[(1-metil-4-nitro-1H-
                                       imidazol-5-il)metil]-4-oxobut-2-en-1-aminium

                                       C24H24Br2ClN9O3




                                                                                                535
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 tenalisibum
 tenalisib                 3-(3-fluorophenyl)-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}-
                           4H-1-benzopyran-4-one

 ténalisib                 3-(3-fluorophényl)-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}-
                           4H-1-benzopyran-4-one

 tenalisib                 3-(3-fluorofenil)-2-{(1S)-1-[(7H-purin-6-il)amino]propil}-4H-
                           1-benzopiran-4-ona

                           C23H18FN5O2

                                                    N
                                              HN
                                   H3C       H           N
                                    O
                                              N      N
                                              H
                                                    F

                                    O



 tetrodotoxinum
 tetrodotoxin              (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-
                           12-(hydroxymethyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a-
                           dimethano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-
                           pentol

 tétrodotoxine             (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-
                           12-(hydroxyméthyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a-
                           diméthano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-
                           pentol

 tetrodotoxina             (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino-
                           12-(hidroximetil)-1,4,4a,5,9,10-hexahidro-7H-5,9:7,10a-
                           dimetano[1,3]dioxocino[6,5-d]pirimidina-4,7,10,11,12-
                           pentol

                           C11H17N3O8




 tezacaftorum
 tezacaftor                1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-
                           dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-
                           2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide




536
WHO Drug Information, Vol. 30, No. 3, 2016                          Recommended INN: List 76




 tezacaftor                            1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-
                                       dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-
                                       2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide

 tezacaftor                            1-(2,2-difluoro-2H-1,3-benzodioxol-5-il)-N-{1-[(2R)-2,3-
                                       dihidroxipropil]-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-
                                       1H-indol-5-il}ciclopropano-1-carboxamida

                                       C26H27F3N2O6




 timolumabum #
 timolumab                             immunoglobulin G4-kappa, anti-[Homo sapiens AOC3
                                       (amine oxidase copper containing 3 (EC 1.4.3.21),
                                       vascular adhesion protein 1, VAP1, VAP-1)],Homo sapiens
                                       monoclonal antibody;
                                       gamma4 heavy chain (1-444) [Homo sapiens VH (IGHV3-
                                       30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -
                                       IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227),
                                       CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-
                                       444)) (118-444)], (131-214')-disulfide with kappa light chain
                                       (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-13*02
                                       (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
                                       214')]; dimer (223-223":226-226")-bisdisulfide

 timolumab                             immunoglobuline G4-kappa, anti-[Homo sapiens AOC3
                                       (amine oxydase à cuivre 3 (EC 1.4.3.21), VAP-1, protéine
                                       d’adhérence vasculaire 1, VAP1, VAP-1)], Homo sapiens
                                       anticorps monoclonal;
                                       chaîne lourde gamma4 (1-444) [Homo sapiens VH
                                       (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-
                                       117) -IGHG4*01 (CH1 (118-215), charnière S10>P (225)
                                       (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442),
                                       CHS (443-444)) (118-444)], (131-214')-disulfure avec la
                                       chaîne légère kappa (1’-214’) [Homo sapiens (V-KAPPA
                                       (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -
                                       IGKC*01, Km3 (108'-214')]; dimère (223-223":226-226")-
                                       bisdisulfure

 timolumab                             inmunoglobulina G4-kappa, anti-[Homo sapiens AOC3
                                       (amina oxidasa con cobre 3 (EC 1.4.3.21), proteína de
                                       adhesión vascular 1, VAP1, VAP-1)],Homo sapiens
                                       anticuerpomonoclonal ;




                                                                                                     537
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016


                           cadena pesada gamma4 (1-444) [Homo sapiens VH
                           (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-
                           117) -IGHG4*01 (CH1 (118-215), bisagra S10>P (225)
                           (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442),
                           CHS (443-444)) (118-444)], (131-214')-disulfuro con la
                           cadena ligera kappa (1’-214’) [Homo sapiens (V-KAPPA
                           (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -
                           IGKC*01, Km3 (108'-214')]; dímero (223-223":226-226")-
                           bisdisulfuro

                            Heavy chain / Chaîne lourde / Cadena pesada
                            QVQLVESGGG VVQPGRSLRL SCAASGFTFF                  SYAMHWVRQT       PGKGLEWVAV        50
                            IWFDGSNENY VDSVKGRFTI SRDNSKNTLY                  LQMNTLRAED       TAVYYCARDA       100
                            WSYFDYWGQG TLVTVSSAST KGPSVFPLAP                  CSRSTSESTA       ALGCLVKDYF       150
                            PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTKTYTC       200
                            NVDHKPSNTK VDKRVESKYG PPCPPCPAPE                  FAGGPSVFLF       PPKPKDTLMI       250
                            SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE                  VHNAKTKPRE       EQFNSTYRVV       300
                            SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE                  KTISKAKGQP       REPQVYTLPP       350
                            SQEEMTKNQV SLTCLVKGFY PSDIAVEWES                  NGQPENNYKT       TPPVLDSDGS       400
                            FFLYSRLTVD KSRWQEGNVF SCSVMHEALH                  NHYTQKSLSL       SLGK             444

                            Light chain / Chaîne légère / Cadena ligera
                            VIQLTQSPSS LSASVGDRVT ITCRASQGIS                  RALAWYQQKP       GKGPKLLIYD 50
                            ASSLESGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       FNSYPLTFGG 100
                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                            LSSPVTKSFN RGEC                                                               214

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H (C23-C104)             22-96       144-200       258-318   364-422
                                                           22''-96'' 144''-200'' 258''-318'' 364''-422''
                            Intra-L (C23-C104)             23'-88'     134'-194'
                                                           23'''-88''' 134'''-194'''
                            Inter-H-L (CH1 10-CL 126) 131-214' 131''-214'''
                            Inter-H-H (h 8, h 11)          223-223'' 226-226''

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            294, 294''
                            Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                            complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


 vadadustatum
 vadadustat                [5-(3-chlorophenyl)-3-hydroxypyridine-
                           2-carboxamido]acetic acid

 vadadustat                acide [5-(3-chlorophényl)-3-hydroxypyridine-
                           2-carboxamido]acétique

 vadadustat                ácido [5-(3-clorofenil)-3-hidroxipiridina-
                           2-carboxamido]acético

                           C14H11ClN2O4




 vadastuximabum #
 vadastuximab              immunoglobulin G1-kappa, anti-[Homo sapiens CD33
                           (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3,
                           gp67, p67)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1-
                           85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo sapiens
                           IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2




538
WHO Drug Information, Vol. 30, No. 3, 2016                         Recommended INN: List 76


                                       S3>C (239) (231-340),CH3 (341-445), CHS (446-447))
                                       (118-447)], (220-214')-disulfide with kappa light chain (1'-
                                       214') [Mus musculus V-KAPPA (IGKV14-111*01 -
                                       IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3
                                       (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide

 vadastuximab                          immunoglobuline G1-kappa, anti-[Homo sapiens CD33
                                       (lectine 3 de type Ig-like liant l’acide sialique, SIGLEC3,
                                       SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique;
                                       chaîne lourde gamma1 (1-447) [Mus musculus VH
                                       (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (118-215), charnière
                                       (216-230), CH2 S3>C (239) (231-340),CH3 (341-445),
                                       CHS (446-447)) (118-447)], (220-214')-disulfure avec la
                                       chaîne légère kappa (1'-214') [Mus musculus V-KAPPA
                                       (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo
                                       sapiens IGKC*01, Km3 (108'-214')]; dimère (226-226'':229-
                                       229'')-bisdisulfure

 vadastuximab                          inmunoglobulina G1-kappa, anti-[Homo sapiens CD33
                                       (lectina de tipo inmunoglobulina 3 que se une al ácido
                                       siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo
                                       monoclonal quimérico;
                                       cadena pesada gamma1 (1-447) [Mus musculus VH
                                       (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo
                                       sapiens IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-
                                       230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS
                                       (446-447)) (118-447)], (220-214')-disulfuro con la cadena
                                       ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV14-
                                       111*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01, Km3 (108'-214')]; dímero (226-226'':229-229'')-
                                       bisdisulfuro




                                                                                                539
Recommended INN: List 76            WHO Drug Information, Vol. 30, No. 3, 2016




 venglustatum
 venglustat                (3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)-
                           1,3-thiazol-4-yl]propan-2-yl}carbamate

 venglustat                N-{2-[2-(4-fluorophényl)-1,3-thiazol-4-yl]propan-
                           2-yl}carbamate de (3S)-1-azabicyclo[2.2.2]octan-3-yle

 venglustat                N-{2-[2-(4-fluorofenil)-1,3-tiazol-4-il]propan-2-il}carbamato
                           de (3S)-1-azabiciclo[2.2.2]octan-3-ilo

                           C20H24FN3O2S

                                                               H
                                                 H3C   CH3 O
                                             N                         N
                            F                           N      O
                                                        H          H
                                            S

 verdiperstatum
 verdiperstat              1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1,2,3,5-
                           tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

 verdiperstat              1-[2-(propan-2-yloxy)éthyl]-2-sulfanylidène-1,2,3,5-
                           tétrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

 verdiperstat              1-[2-(propan-2-iloxi)etil]-2-sulfanilideno-1,2,3,5-tetrahidro-
                           4H-pirrolo[3,2-d]pirimidin-4-ona

                           C11H15N3O2S




 vobarilizumabum #
 vobarilizumab             immunoglobulin scFv VH-VH’, anti-[Homo sapiens IL6R
                           (interleukin 6 receptor, IL-6R, CD126)] and anti-[Homo
                           sapiens ALB (albumin, human serum albumin, HSA)],
                           humanized monoclonal antibody bispecific single chain;
                           scFv (1-245) [humanized VH anti-IL6R (Homo sapiens
                           IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-
                           121) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (122-130)
                           -humanized VH’ anti-ALB (Homo sapiens IGKV3-23*04
                           (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

 vobarilizumab             immunoglobuline scFv VH-VH’, anti-[Homo sapiens IL6R
                           (récepteur de l'interleukine 6, IL-6R, CD126)] et anti-[Homo
                           sapiens ALB (albumine, sérum-albumine humaine, SAH)],
                           anticorps monoclonal humanisé et bispécifique à chaîne
                           unique;
                           scFv (1-245) [VH humanisé anti-IL6R (Homo sapiens
                           IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-
                           121) -9-mer tétraglycyl-séryl-triglycyl-séryl linker (122-130)
                           -VH’ humanisé anti-ALB (Homo sapiens IGKV3-23*04
                           (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]



540
WHO Drug Information, Vol. 30, No. 3, 2016                           Recommended INN: List 76




 vobarilizumab                         inmunoglobulina scFv VH-VH’, anti-[Homo sapiens IL6R
                                       (receptor de la interleukina 6, IL-6R, CD126)] y anti-[Homo
                                       sapiens ALB (albúmina, albúmina sérica humana, ASH)],
                                       anticuerpo monoclonal humanizado biespecífico
                                       monocatenario;
                                       scFv (1-245) [VH humanizado anti-IL6R (Homo sapiens
                                       IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-
                                       121) -9-mer tetraglicil-seril-triglicil-seril vínculo (122-130) -
                                       VH’ humanizado anti-ALB (Homo sapiens IGKV3-23*04
                                       (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]




 xentuzumabum #
 xentuzumab                            immunoglobulin G1-lambda1, anti-[Homo sapiens IGF1
                                       (insulin-like growth factor 1, somatomedin C) and IGF2
                                       (insulin-like growth factor 2, somatomedin A)], humanized
                                       monoclonal antibody;
                                       gamma1 heavy chain (1-447) [humanized VH (Homo
                                       sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01)
                                       [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215),
                                       hinge (216-230), CH2 (231-340), CH3 (341-445), CHS
                                       (446-447)) (118-447)], (220-215')-disulfide with lambda1
                                       light chain (1'-216') [humanized V-LAMBDA (Homo
                                       sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-
                                       110') -IGLC2*01 A43>G (154) (111'-216')]; dimer (226-
                                       226'':229-229'')-bisdisulfide

 xentuzumab                            immunoglobuline G1-lambda1, anti-[Homo sapiens IGF1
                                       (facteur de croissance 1 analogue à l’insuline,
                                       somatomédine C) et IGF2 (facteur de croissance 2
                                       analogue à l’insuline, somatomédine A)], anticorps
                                       monoclonal humanisé;
                                       chaîne lourde gamma1 (1-447) [VH humanisé (Homo
                                       sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01)
                                       [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215),
                                       charnière (216-230), CH2 (231-340), CH3 (341-445), CHS
                                       (446-447)) (118-447)], (220-215')-disulfure avec la chaîne
                                       légère lambda1 (1'-216') [V-LAMBDA humanisé (Homo
                                       sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-
                                       110') -IGLC2*01 A43>G (154) (111'-216')]; dimère (226-
                                       226'':229-229'')-bisdisulfure

 xentuzumab                            inmunoglobulina G1-lambda1, anti-[Homo sapiens IGF1
                                       (factor de crecimiento 1 análogo a la insulina,
                                       somatomedina C) y IGF2 (factor de crecimiento 2 análogo
                                       a la insulina, somatomedina A)], anticuerpo monoclonal
                                       humanizado;




                                                                                                    541
Recommended INN: List 76                 WHO Drug Information, Vol. 30, No. 3, 2016




                           cadena pesada gamma1 (1-447) [VH humanizado (Homo
                           sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01)
                           [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215),
                           bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS
                           (446-447)) (118-447)], (220-215')-disulfuro con la cadena
                           ligera lambda1 (1'-216') [V-LAMBDA humanizado (Homo
                           sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-
                           110') -IGLC2*01 A43>G (154) (111'-216')]; dímero (226-
                           226'':229-229'')-bisdisulfuro


                            Heavy chain / Chaîne lourde / Cadena pesada
                            QVELVESGGG LVQPGGSLRL SCAASGFTFT                  SYWMSWVRQA       PGKGLELVSS        50
                            ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARNM       100
                            YTHFDSWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                            PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                            NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                            LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                            RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                            LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                            DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                            Light chain / Chaîne légère / Cadena ligera
                            DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG                  SNSVSWYQQL       PGTAPKLLIY 50
                            DNSKRPSGVP DRFSGSKSGT SASLAITGLQ                  SEDEADYYCQ       SRDTYGYYWV 100
                            FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ                  ANKATLVCLI       SDFYPGAVTV 150
                            AWKGDSSPVK AGVETTTPSK QSNNKYAASS                  YLSLTPEQWK       SHRSYSCQVT 200
                            HEGSTVEKTV APTECS                                                             216

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            Intra-H (C23-C104)        22-96       144-200       261-321   367-425
                                                      22''-96'' 144''-200'' 261''-321'' 367''-425''
                            Intra-L (C23-C104)        22'-89'     138'-197'
                                                      22'''-89''' 138'''-197'''
                            Inter-H-L (h 5-CL 126) 220-215' 220''-215'''
                            Inter-H-H (h 11, h 14) 226-226' 229-229''

                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                            H CH2 N84.4:
                            297, 297''
                            Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
                            complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados




 zoliflodacinum
 zoliflodacin              (2'R,4'S,4'aS)-11'-fluoro-2',4'-dimethyl-8'-[(4S)-4-methyl-
                           2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tetrahydro-
                           6'H-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-
                           a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione

 zoliflodacine             (2'R,4'S,4'aS)-11'-fluoro-2',4'-diméthyl-8'-[(4S)-4-méthyl-
                           2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tétrahydro-
                           6'H-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-
                           a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione

 zoliflodacina             (2'R,4'S,4'aS)-11'-fluoro-2',4'-dimetil-8'-[(4S)-4-metil-2-oxo-
                           1,3-oxazolidin-3-il]-1',2',4',4'a-tetrahidro-6'H-spiro[1,3-
                           diazinano-5,5'-[1,4]oxazino[4,3-a][1,2]oxaz-olo[4,5-
                           g]quinolina]-2,4,6-triona

                           C22H22FN5O7




542
WHO Drug Information, Vol. 30, No. 3, 2016                              Recommended INN: List 76




                        AMENDMENTS TO PREVIOUS LISTS
               MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                   MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)
 
p. 58    lonaprisanum
         lonaprisan            replace the chemical name by the following one
         lonaprisan            remplacer le nom chimique par le suivant
         lonaprisán            sustitúyase el nombre químico por el siguiente

                               11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-
                               17α-pregna-4,9-dien-3-one

                               11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-
                               17α-prégna-4,9-dién-3-one

                               11β-(4-acetylfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-
                               17α-pregna-4,9-dien-3-ona

Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)
 
p. 58    daclatasvirum
         daclatasvir           replace the chemical name by the following one
         daclatasvir           remplacer le nom chimique par le suivant
         daclatasvir           sustitúyase el nombre químico por el siguiente

                               dimethyl N,N'-([1,1'-biphenyl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)-
                               pyrrolidine-2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate
                               N,N'-([1,1'-biphényl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)-
                               pyrrolidine-2,1-diyl][(2S)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate
                               de diméthyle

                               N,N'-([1,1'-bifenil]-4,4'-diilbis{1H-imidazol-5,2-diil-[(2S)-pirrolidina-
                               2,1-diil][(2S)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

Recommended International Nonproprietary Names (Rec. INN): List 71




                                                                                                       543
Recommended INN: List 76                                  WHO Drug Information, Vol. 30, No. 3, 2016


Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)
 
p. 90      idarucizumabum
- 91       idarucizumab               replace the description by the following one
           idarucizumab               remplacer la description par la suivante
           idarucizumab               sustitúyase la descripción por la siguiente

                                      immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized
                                      monoclonal antibody;
                                      VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (Homo
                                      sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -
                                      Homo sapiens IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-
                                      225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized
                                      V-KAPPA (Homo sapiens IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9]
                                      (1'-112') -Homo sapiens IGKC*01 (113'-219')]

                                      immunoglobuline Fab G1-kappa, anti-[dabigatran], anticorps
                                      monoclonal humanisé;
                                      chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH
                                      humanisé(Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01)
                                      [8.7.16](1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), charnière
                                      1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère
                                      kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*01
                                      (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
                                      219')]

                                      inmunoglobulina Fab G1-kappa, anti-[dabigatrán], anticuerpo
                                      monoclonal humanizado;
                                      cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado
                                      (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16]
                                      (1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-
                                      225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-
                                      219') [V-KAPPA humanizado (Homo sapiens IGKV2-30*01 (88.00%)-
                                      IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]




    Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios
    generales
    The text of the Procedures for the Selection of Recommended International Nonproprietary Names for
    Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary
    Names for Pharmaceutical Substances will be reproduced in proposed INN lists only.
    Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales
    recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de
    dénominations communes internationales applicables aux substances pharmaceutiques seront publiés
    seulement dans les listes des DCI proposées.
    El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas
    para las sustancias farmacéuticas y de los Principios generales de orientación para formar
    denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las
    listas de DCI propuestas.




544
